2016 U-M Kellogg Eye Center Annual Report

UNIVERSITY OF MICHIGAN W.K. KELLOGG EYE CENTER

Extending Frontiers in Vision

~ Our Purpose ~ To improve lives through curing, preventing, and treating eye disease

2016 ANNUAL REPORT

Extending Frontiers in Vision University of Michigan Kellogg Eye Center Annual Report 2016

3

22

6

24

25

Research to Restore Vision

Education

New Faculty and Our Trainees

3

19 Grand Rounds Finds

a Broader Audience

28 Kellogg's New Faculty

Studying the Zebrafish

5 Kellogg’s 2016 K Award Recipients 6

Kellogg is Home to Three 2016 RPB Award Winners

8 Research by Ophthalmology

Residents and Post-Doctoral Fellows

Patient Care Innovation with Global Impact 11 From Shipping Container

to Ophthalmology Clinic 12 Lessons from India’s

High Volume, High Quality

Cataract Surgery Model 14 Pediatric Ophthalmology Update

20 Kellogg’s Global Impact

Showcased at International Night 22 Alumni Weekend 2016

Philanthropy in Support of Kellogg 24 Dr. Sayoko Moroi Named

Jerome Jacobson Professor 25 Wheeler Family Honors First

African-American U-M Professor

with Endowment

29 2016 Graduating Residents 29 2016 Graduating Clinical Fellows 30 2016 First Year Post-doctoral Fellows

Faculty Honors and Recognition, Publications, and External Grants and Funding 31 Honors and Recognition 34 Publications

26 Ida Iacobucci Honored for

a Lifetime of Devotion to Kellogg

43 External Grants and Funding

27 Musson Family Helps Establish

Legacy Fund

48 2016 Kellogg Eye Center Faculty,

Residents and Fellows

16 Clinical Trials Update For patient appointments, please call 734.763.8122.

Front cover clockwise from the top Left: Michael R. Petersen, M.D., Ph.D.; Shahzad Mian, M.D.; Hong-Gam Le, M.D.; Alma Wheeler Smith; Sophia Wang, M.D.; Donald Puro, M.D., Ph.D. *This report covers the time period of July 1, 2015 through September 30, 2016.

Clinic phone numbers are online at umkelloggeye.org

The Chair’s Perspective Dear Friends,

At first glance, zebrafish, shipping containers, and access to

our Grand Rounds on your smartphone would appear to have little in common. Yet in 2016, each played a role in innovative approaches to research, clinical care, and education at Kellogg.

In this Annual Report, we hope that you will enjoy learning about our recent work towards improving the lives of our patients by curing, preventing and treating eye disease.

Basic science forms the foundation of our knowledge to

Front row: Denise John, M.D., director of VA Hospital Eye Care; Alan Sugar, M.D, vice-chair; Back row: Thiran Jayasundera, M.D., director of strategic planning; Michael Smith-Wheelock, M.D., associate chair for clinical affairs; Paul Lee, M.D., J.D., chair; Thomas Gardner, M.D., M.S., associate chair for research; and Shahzad Mian, M.D. associate chair for education

develop new therapies. To understand mechanisms of ocular development, Kellogg scientists are studying zebrafish because of their fast rate of growth and ability to regenerate damaged tissues. Exciting work is also coming from two faculty members who received prestigious Research to Prevent Blindness (RPB) grants to pursue their ideas about dry eyes and light sensation.

Knowledge gleaned in the laboratory needs to be translated

colleagues at the Aravind Eye Hospital in India, how to deliver

into new products, devices and services. In this past year,

eye care more efficiently.

Kellogg faculty and trainees received nine patents and submitted

many more invention disclosures for patenting.

date on the latest in diagnosis and management of diseases and

conditions. A tool to help is our new “eBlast” program. Grand

Treatments must be evaluated rigorously through clinical

trials. The Kellogg Clinical Research Center is growing significantly. As with all of our work, its success is based on a team approach. In this year’s report, we are pleased to introduce you to our clinical research coordinators and to provide a sampling of some of our clinical trials actively enrolling patients. To find out more about these and other trials, visit

As busy practitioners, it can be challenging to stay up to

Rounds cases are encapsulated into a short email summary

“Together we are extending the frontiers of vision care.”

Our Center for Eye Care Policy and Innovation has

readily available to interested health care professionals.

At this year’s Alumni Reunion, our Farjo Lecturer was Dr. Paul Sieving, the Director of the National Eye Institute and

—Paul P. Lee, M.D., J.D.

former faculty member at Kellogg, who described his journey from addressing basic

kellogg.umich.edu/research/kcrc.html

easily viewed on a mobile device and

science questions to implementing a gene therapy trial for

fortified our understanding of the many challenges that keep

x-linked retinoschisis. This path of discovering basic principles,

patients from benefitting from proven care. You can read about

translation to new therapies, and validation in clinical trials

our efforts to improve vision screening for children and to use

is a model from which we develop ways to prevent and treat

telemedicine for the diagnosis and care of premature babies

eye disease.

at risk for retinopathy of prematurity. Two new NIH K23

awardees are developing personalized approaches to diagnostic

would not be possible without our partnerships with all of

testing and patient-centered education that bolsters patient

you—our loyal alumni, patients and their families, supporters,

involvement in health care. Kellogg is proud to be among

and colleagues. We are grateful. Together we are extending the

programs with the highest number of such training awards.

frontiers of vision care.

The efforts of our outstanding faculty, staff and trainees

In responding to a need for eye care facilities in Jamaica,

colleagues from schools and units throughout the University partnered to create the first Michigan eye clinic in a shipping

2

container. The result of their collaboration has been in use

Paul P. Lee, M.D., J.D.

at Sandy Bay, Jamaica since the fall of 2016. The container

F. Bruce Fralick Professor and

provides space for examinations and glasses dispensing. We

Chair, Ophthalmology and Visual Sciences

are learning from our international partners, including our

Director, W.K. Kellogg Eye Center

Basic Science in Focus

Studying the Zebrafish With its rapid incubation and long list of

genetic features, the humble zebrafish is

of mutations to PITX2 and PAX6, the former known to lead

assisting Kellogg researchers in groundbreaking basic science to regenerate the eye.

The zebrafish has become the focus of research in several laboratories at Kellogg Eye Center.

What makes it the perfect animal model for ophthalmol-

ogy? Unlike mice or other mammals, zebrafish embryos are transparent and develop outside of the mother’s body. Moreover, zebrafish progress from single-cell fertilized eggs to a developed, hatched organism in just five days. Such features allow investigators to observe zebrafish development and manipulate their genetic makeup in real time.

Zebrafish also provide an ideal platform to study cells

with specific generative properties relevant to eye development, including neural crest, muscle, and Müller glia cells.

Dr. Bohnsack is applying the same approach in her study

to Axenfeld-Rieger syndrome and the latter linked to aniridia.

In addition to singling out genetic mutations, her lab is looking at the role collagens play in conditions like Stickler syndrome, a hereditary multisystem disease that involves the eye, and osteogenesis imperfecta (“brittle bone disease”) to understand how collagens influence eye development.

“Our hope,” Dr. Bohnsack says, “is that this work will

eventually lead to breakthroughs in genetic testing and new therapeutic approaches to prevent blindness in children affected by these congenital diseases.”

Building on her understanding of the genetic origins of

eye development, Dr. Bohnsack also wants to know whether the same genes may play a role in the structure and function of the adult eye. For her work in this emerging area, Bohnsack was awarded a 2016 Alcon Research Institute Young Investigator Grant.

Studying the anterior segment To assistant professor Brenda Bohnsack, M.D., Ph.D., congenital diseases of the eye’s anterior segment hold the key to understanding how the eye develops. Dr. Bohnsack uses zebrafish to study neural crest cells, early embryonic cells from which many of the structures in the anterior segment are derived. She investigates the genes that regulate ocular neural crest migration, proliferation and differentiation, along with mutations in those genes known to give rise to problems with eye formation.

One example is the gene CYP1B1, which, when mutated,

is known to cause primary infantile-onset glaucoma. “Despite all we know about CYP1B1,” Dr. Bohnsack explains, “no one has yet described its role in eye development. That’s one area where we’re breaking new ground here at Kellogg.”

Brenda Bohnsack, M.D., Ph.D., assistant professor of Ophthalmology (left), with her laboratory group 3

“While all of these studies are pre-clinical, stem cell therapy is clearly on the horizon in ophthalmology.”

—Peter Hitchcock, Ph.D.

Studying the orbit Associate professor Alon Kahana, M.D., Ph.D., an oculoplastic surgeon who specializes in orbital disease, is using zebrafish to better understand the biology of orbital disease, with a focus on stem cells, tissue regeneration, and cancer.

A pioneer in the use of zebrafish to study the orbit and

periocular structures, Dr. Kahana’s research takes advantage of the unique characteristics of adult zebrafish to study the biology of strabismus and repair of the muscles that move the eyes following injury or disease. Using an innovative model developed in his lab, Dr. Kahana is able to use genomic and epigenetic analyses to study how to coax damaged tissues to regenerate and recover function.

“Eye movement in both humans and zebrafish is controlled

by the same six pairs of extraocular muscles,” he explains.

“Disorders in these muscles result in amblyopia in children and double vision in adults. We have identified a number of pathPeter Hitchcock, Ph.D., professor of Ophthalmology (left), with his laboratory group

Studying the retina Another advantage of studying zebrafish is that the retina in all vertebrates, whether fish or human, is quite similar. Professor Peter Hitchcock, Ph.D. is using zebrafish to answer two questions: How is the retina formed? Can essential cells in the retina be regenerated?

To study retinal formation, Dr. Hitchcock was an early

adopter of technologies like CRISPR-Cas, a genome editing tool that allows researchers to introduce changes directly into an organism’s genome. “In zebrafish, we use a CRISPR-Cas system to disable select genes, creating different mutations,” he explains. “It’s a revolutionary tool for analyzing the molecular mechanisms governing the retina’s development.”

Dr. Hitchcock’s lab is also looking for ways to translate

particularly advantageous characteristics of zebrafish into

ways through which zebrafish can regenerate fully functional muscles even after up to 80 percent of the muscle is lost.”

Dr. Kahana believes that translating findings from zebrafish

to humans will result in improved treatments of disorders that affect eye alignment, in effect allowing the body to heal itself.

The biology of zebrafish regeneration appears to share

many commonalities with cancer. “The genetic and epigenetic changes that occur in zebrafish stem cells mimic, to a large extent, the biology of cancer stem cells,” he explains. “It’s a truly remarkable finding that has led to an important collaboration with top cancer researchers at Michigan, including Dr. Max Wicha.”

Dr. Kahana is also actively translating his findings in zebra-

fish to human eye disorders. “Using zebrafish, we discovered that thyroid eye disease (also known as Graves eye disease) may be caused by a unique biological interaction between thyroid hormone and neural crest-derived cells in the orbit, resulting in ‘hijacking’ of the immune system’s inflammatory response.”

humans. Within the retina of the zebrafish are intrinsic stem cells called Müller glia, which have the ability to regenerate new photoreceptors after injury. Human retinas have Müller glia cells as well, but have no such regenerative capacity.

“One way to achieve regeneration is to transplant exog-

enous stem cells fated to make photoreceptor cells into an injured retina,” Dr. Hitchcock says. “Another is to understand how zebrafish Müller glia behave like stem cells, then induce human Müller glia to do the same.”

Dr. Hitchcock is also developing a similar model to study

the regenerative potential of retinal ganglion cells destroyed in glaucoma. “While all of these studies are pre-clinical,” he says, “stem cell therapy is clearly on the horizon in ophthalmology.”

4

Alon Kahana, M.D., Ph.D., associate professor of Ophthalmology (fifth from left), with his laboratory group

Kellogg’s 2016 K Award Recipients Two Kellogg Eye Center faculty members received National

Paula Anne Newman-

Institutes of Health Research Career Development Awards,

Casey, M.D., M.S.

or K awards, in 2016. Both are contributing to the evolving

At least half of glaucoma patients

field of precision ophthalmology— developing novel tools that

to improve their medication

8

2015

10

to motivate glaucoma patients

adherence. rate retinal degenerative diseases.

“We know that education is essential to improving adherover 10 years In his clinic, he encounters chal-

ence,” Dr. Newman-Casey says. “But we need to find a more

lenges and limitations of current

efficient way to educate patients than relying upon a lengthy

testing standards when determin-

conversation with a physician.”

ing treatments and responses to

2 201

2M 11.

2012

14 20

10

00 ,1

0 136,60

10

2015

14.6 M

14 20

.6M 13

13 common barriers to medication adherence.” as a glaucoma counselor, patients talk through their experience with glau-

coma and their problems with adequately

2013

1 01

2012

14M

85

symptoms and daily functioning.

Patients will be guided through a survey developed

9.5M

patient reports about various vision-related

“It also contains an archive of

Guided by a technician trained 10 M

patients by taking into account what a

patient’s profile,” she explains. recorded stories about how various

2010

ing which retinal tests to perform on

that can be matched to an individual

de-identified patients overcame

80%

72

new clinical solution for determin-

demographics, test results and treatments

20 11

2

K award will develop and test a

“eyeGuide contains a library of factors like

20 08

growth rate over 10 years

David Musch, Ph.D. and Thomas Gardner, M.D., Dr. Jayasundera’s

2007

Research Funding

61

2010

growth

Under the mentorship of ver 10 years

8.1 M

2 201

1 01

us in the right direction.” rate

help nonadherent patients take their medication.

09 20

61

2009

Facultying, much of which may not point

program designed by Dr. Newman-Casey and her team to

M 7.8

08

subjecting patients to hours of test-

eyeGuide, a computer-based, personalized behavior-change

8.1M

16 20

there must be a better approach than

Under the mentorship of Michele Heisler, M.D. and

Paul Lee, M.D., J.D., the project will refine and pilot test the 9

2013

12 7

“There are an overwhelming

9

2

treatments.

201 1

200%

2007 set, progression or treatment response, 20

research in technology-based, individually-tailored programs

2010

clinical practice focus Professorships on

the function of retinal and post-retinal visual path61 ways,” he explains. “While we don’t wish to .6M 14 5 omit any test9 that might show disease on-

66%

K award will support her ongoing

2007 20 08

Dr. Jayasundera’s research Endowed and

number of psychophysical and electrophysiological tools to test

16

disease. Dr. Newman-Casey’s

inherited and inflammatory growth 114,5 00

2010

72%

,400 115

2009

growth rate ver 10 years

significant hurdle to treating the

5

09 20

08

atient Visits

do not take their medication, a 4

6

0 40

16

into account an individual patient’s unique characteristics 11take 4,60 0 in order to better diagnose, treat, and manage eye diseases.

12 11 5, 2007 16 K. Thiran Jayasundera, 20 20 M.D., F.A.C.S.

managing the disease. This helps glaucoma patients find their own motivation to overcome barriers to controlling the disease.

To better integrate education and counseling into a pa-

by Dr. Jayasundera called the Progression of Retinal Degenera-

tient’s clinic visit, the team is also applying operations engineer-

tion Questionnaire (PDRQ). Patients’ responses will help direct

ing principles like workflow and scheduling analysis to identify

more targeted testing. The project includes validating a PRDQ

ways to use patient wait times as educational opportunities.

clinical-testing protocol in patients with autoimmune retinopa-

Such analyses will inform future iterations of the eyeGuide

thy, a condition that is poorly understood.

program.

5

“Thousands of the patients I see

in my clinic suffer from dry eye. It’s a constant frustration to have so few therapeutic options to offer them. The RPB award gives me an opportunity to look at the problem

”

from a different angle.

—Donald Puro, M.D., Ph.D. Donald Puro, M.D., Ph.D., professor of Ophthalmology

Kellogg is Home to Three 2016 RPB Award Winners Research to Prevent Blindness (RPB) is the leading voluntary health organization supporting research to prevent, treat or eradicate all diseases that threaten vision. Its researchers have been associated with nearly every major breakthrough in understanding and treating vision loss in the past 50 years.

The Kellogg Eye Center is one of only three institutions to have three investigators recognized with RPB awards in 2016.

He is focusing on conjunctival goblet cells and the mecha-

nisms by which ion channels affect them. Although goblet cell death is responsible for irreversible mucin deficiency late in the course of dry eye, Dr. Puro hypothesizes that goblet cell function is altered by hyperosmolarity at an earlier, potentially reversible stage of the disorder.

“My study aims to build on the knowledge base of goblet

cell function,” Dr. Puro says. “Eventually, I hope it will help us identify new therapeutic targets for more effective treatments of dry eye.”

The RPB Stein Innovation Award: Donald Puro, M.D., Ph.D. A novel experimental approach to dry eye: the role of ion channels in the physiology and pathobiology of conjunctival goblet cells

Paula Anne Newman-Casey, M.D, M.S., assistant professor of Ophthalmology

Although professor Donald Puro has devoted his career to retinal research and a clinical practice focused on diabetic retinopathy, he received an RPB grant to study a different but related problem: dry eye.

“Thousands of the patients I see in my clinic suffer from

dry eye,” Dr. Puro says. “It’s a constant frustration to have

6

RPB Career Development Award: Paula Anne Newman-Casey, M.D., M.S. Leveraging eHealth technologies and personally tailored information to improve patients’ ability to

so few therapeutic options to offer them. The RPB award

self-manage glaucoma: an integrative design approach

provides me with an opportunity to look at the problem

Assistant professor Paula Anne Newman-Casey will use the RPB

from a different angle.”

Career Development Award to take on a significant challenge in

the care of glaucoma patients: poor medication adherence.

One reason few treatments exist for dry eye is a gap in

understanding how cells on the ocular surface respond to

hyperosmolarity. Dr. Puro’s idea builds on the observation

minorities and elderly patients are essentially ‘untreated’ because

that an increase in the osmotic concentration of tears is the

they do not adhere to their medication plans,” Dr. Newman-

hallmark of dry eye.

Casey says.

“At least half of patients and a disproportionate number of

“This novel synaptic pathway could

be leveraged to enhance the light-sensing capability of blind and/or low-vision

”

individuals.

—Kwoon Wong, Ph.D.

Kwoon Wong, Ph.D., assistant professor of Ophthalmology

“When it comes to getting patients to take their medica-

For more than a century, it was thought that light-driven

tions, we know that ‘one size fits all’ approaches don’t work,

signals in the retina were transmitted in only one direction: from

but detailed, individualized counseling can be helpful,” Dr.

the rods and cones toward amacrine interneurons in the inner

Newman-Casey adds.

retina, then from the interneurons to ganglion cells. Ganglion

cells subsequently send messages through the optic nerve to the

“The reality is that few busy clinics can allocate enough

face-to-face physician time for that kind of personalized educa-

rest of the brain.

tion,” she continues. “Technology is the bridge to individual-

izing and delivering the messages that will most effectively help

team that discovered the first instance of retinal signaling in

patients effect change.”

the opposite direction, from intrinsically photosensitive retinal

ganglion cells (ipRGCs) to one type of amacrine interneuron.

Working with a multidisciplinary team, Dr. Newman-Casey

During his postdoctoral studies, Dr. Wong was part of a

has developed a prototype of a web-based, personally tailored

behavior-change program called eyeGuide that can be delivered

demonstrated that ipRGCs send signals to many additional types

to glaucoma patients by paraprofessional staff with basic train-

of amacrine interneurons. The RPB award will help fund Dr.

ing in a counseling style called motivational interviewing.

Wong’s efforts to elucidate the functional roles of ipRGC-to-

amacrine transmission and its impact on retinal physiology and

The RPB award makes it possible for Dr. Newman-Casey

In subsequent studies in Dr. Wong’s lab at U-M, his team

to expand the eyeGuide from its current text-based format into

visual behavior.

a multimedia platform and test it in a clinical setting. She will

partner with integrative design students from the U-M Stamps

the long-held belief that ganglion cells communicate only to

School of Art & Design to refine eyeGuide’s web-based user

higher visual centers of the brain,” Dr. Wong explains. “That

interface to work in concert with clinic work flow. She will

discovery opens up an exciting new area of research.” Dr. Wong

then test eyeGuide’s impact on medication adherence and key

believes that this finding may be relevant to the fight against

psychological factors that influence adherence, as well as on

blindness, because ipRGCs continue to be light-sensitive in many

outcomes, including intraocular pressure and changes in clinical

blind patients suffering outer retinal dysfunction. He also points

management.

to mouse studies indicating that intraretinal signaling remains

“The discovery of intraretinal signaling by ipRGCs refutes

intact in the face of rod/cone degeneration. “This novel synaptic RPB Special Scholar Award: Kwoon Wong, Ph.D. Intraretinal signaling by intrinsically photosensitive retinal ganglion cells

pathway could be leveraged to enhance the light-sensing capability of blind and/or low-vision individuals,” he says.

Dr. Wong’s work with photoreceptive retinal ganglion cells

was also recognized with the 2016 ARVO Foundation for Eye

The RPB Special Scholar Award will make it possible for as-

Research Pfizer Ophthalmics Carl Camras Translational

sistant professor Kwoon Wong to expand his groundbreaking

Research Award. In addition to its potential to improve condi-

research into how different categories of retinal cells communi-

tions for the blind, his research could accelerate the develop-

cate information about light and how the retina translates

ment of healthier indoor lighting, as well as better phototherapy

that information into visual images.

devices for treating seasonal affective disorder and jet lag.

7

Research by Ophthalmology Residents and Post-Doctoral Fellows

Sophia Wang, M.D. Screening for Diabetic Retinopathy in Children and Adolescents

Third-year resident Sophia Wang, M.D. is utilizing a large health insurance claims database to examine guidelines for diabetic retinopathy screening. Under the guidance of her health services research mentor, associate professor Joshua Stein, M.D., M.S., Dr. Wang hopes to determine if the recommended timing of screenings results in delayed diagnosis and whether racial and socioeconomic factors impact younger patients’ access to screening.

Writing Award

Dr. Wang’s research writing skills were recognized in 2016 with the Ophthalmology Times Resident Writers Award for her manuscript, “10 Tips for TEN: Treatment of Ocular Surface Disease Associated With Toxic Epidermal Necrolysis,” which she completed under the mentorship of professor Shahzad Mian, M.D. 8

Jason Miller, M.D., Ph.D.

Origins of Dry Age-Related Macular Degeneration

There are no FDA-approved therapies available to treat patients with the dry form of age-related macular degeneration (AMD). Dry AMD lab studies are especially challenging because there are no good non-primate animal models.

In the laboratory of first-year ophthalmology resident Jason Miller, M.D., Ph.D., work is underway on new models of dry AMD using retinal pigmented epithelium (RPE) extracted from donated human tissue.

These models allow Dr. Miller to study drusen and lipofuscin, two lipid-rich trash deposits in and around the RPE that are hallmarks of dry AMD. The RPE performs an essential task in preserving sight. Each day the eye’s photoreceptors shed a lipid-rich portion of their contents called outer segments that no longer fully absorb light. The

RPE collects those cast-off fragments, breaks them down, and recycles their components back to the photoreceptors, enabling the photoreceptors to make new light-detecting outer segments. With age, the RPE’s ability to degrade and recycle outer segments may diminish, resulting in the buildup of lipofuscin deposits, known as drusen, inside and outside the RPE cells.

“In our model, we are able to stress the RPE in ways that mimic the development of dry AMD,” Dr. Miller explains. “One way is to overload the RPE cultures with outer segments. At that point, signs of AMD are evident, including lipofuscin and drusen secretions.”

Under the mentorship of professors Debra Thompson, Ph.D. and professor David Zacks, M.D., Ph.D., Miller’s team is also working to identify cell pathways that could help the RPE do its job more efficiently, which may eventually lead to the development of treatments for dry AMD.

Monica Diaz Corรกnguez, Ph.D.

Restoring Retinal Vascular Barriers in Diabetic Retinopathy

The research of postdoctoral fellow Monica Diaz Corรกnguez, Ph.D. studies mechanisms that lead to vascular dysfunction in diabetic retinopathy under the mentorship of professor David Antonetti, Ph.D. Vascular endothelial growth factor (VEGF) contributes to the loss of the normal barrier function of the retinal blood vessels, causing these vessels to leak and lead to loss of vision.

Dr. Diaz Corรกnguez discovered that norrin, a cytokine produced as part of normal retinal blood vessel development, is able to counteract VEGF-induced vascular dysfunction. Her work using cells in culture demonstrates how norrin and VEGF interact to promote proper barrier function.

In two animal models of diabetes, she has demonstrated that norrin can restore normal retinal-vessel barrier properties, suggesting the promise of norrin as a new therapy to restore normal vascular function in patients with diabetic retinopathy.

10

From Shipping Container to Ophthalmology Clinic

Joseph Myers, O.D., flanked by Nita Valikodath, U-M 4th year medical student (left) and Matthew Manry, M.D., former U-M ophthalmology resident

Pursuing the vision of a University Health Service staff optometrist, Kellogg faculty members and resident trainees in ophthalmology teamed with U-M professors of architecture to create an ophthalmic care facility in Jamaica.

funded by a grant from the Third Century Initiative, which

When Joseph Myers, O.D. is not caring for students at

marks U-M’s 2017 bicentennial and supports creative teaching

the University Health Service, he is focused on the needs of

and scholarship opportunities that address the world’s greatest

patients 1,700 miles away in Jamaica. Since co-founding the

challenges.

Eye Health Institute (EHI) on the island in 2001 with Colorado

optometrist Richard Cross, Dr. Myers’ mission trips inspired

to area residents. Volunteer optometric and ophthalmic special-

him and his colleagues at EHI to launch a remarkable project.

ists conduct exams, perform corrective procedures, and make

glasses. According to Dr. Myers, much of the project’s success

At one time, the residents of Sandy Bay had little access

The Sandy Bay Clinic now brings a high level of eye care

to eye care. In May 2016, Kellogg sent a team of eye care

is due to the partnership with the Kellogg Eye Center and with

providers that included Donna Wicker, O.D., U-M assistant

David Burke, Ph.D., U-M professor of Human Genetics.

professor and director of the Kellogg Optometry and Low

Vision section. “Early trips showed us just how great the area’s

contents so that “offspring” models can be used elsewhere.

needs were,” Dr. Myers remarked. “No matter how many

Meanwhile, the ARC affords Kellogg a unique platform to

exams we performed or pairs of glasses we made, we could help

teach, learn, train, and conduct research. Kellogg physicians

only a fraction of the hundreds who lined up for our services.”

are developing protocols to train local residents in ocular

testing and imaging, and are studying the impact the project

The challenge was shared with Geoffrey Thün, U-M

associate professor of Architecture and associate dean for

Professor Thün hopes to refine the container and its

is having on the health of the community.

research, and Kathy Velikov, U-M associate professor of Architecture. For a relatively modest cost, could they modify a 20 X 8-foot recycled shipping container into a fully functional clinic environment outfitted in the United States and shipped, unpacked, and set up anywhere in world?

The ARC lands in Jamaica The resulting clinic, called an architecturally repurposed container (ARC), was shipped to Jamaica in June 2016 and assembled in just 72 hours by Dr. Myers and a team of local volunteers.

The project was supported by Global REACH, the

U-M Medical School’s platform to facilitate and promote international research, education and collaboration. It was

Donna Wicker, O.D., assistant professor of Ophthalmology (right), tests reading visual acuity on a patient at the Sandy Bay Clinic in Jamaica 11

Lessons From India’s High Volume, High Quality Cataract Surgery Model

Hong-Gam Le, M.D. (center), former U-M medical student, with mid-level ophthalmic personnel at Aravind

Kellogg investigators have established a novel collaboration

About the study

with Aravind, India’s largest private eye care hospital system,

The analysis was based on a random sample of 292 of the

aiming to learn some lessons from one of the most efficient

10,954 outpatients who had undergone phacoemulsification

eye care providers in the world.

cataract surgery at the Aravind Eye Hospital in Madurai, India,

in July 2013. Data were collected on preoperative and postop-

The Aravind Eye Care System operates 11 hospitals across

India. In the year ending in March 2016, 3.7 million outpa-

erative vision, resources used during each surgery, the type of

tients were treated and more than 408,000 surgeries were

intraocular lens, and total cost.

performed, including more than 260,000 cataract surgeries.

Health was adapted to capture health-related quality-of-life

Soon after its founding in 1979, Aravind began its partner-

A survey approach validated by the National Institutes of

ship with the University of Michigan. Since then Aravind lead-

measures before and one month after surgery. The study also

ers have trained at the U-M schools of medicine, business, and

factored in life expectancy data to calculate lifetime quality-

public health. Kellogg Eye Center faculty members and trainees

adjusted life-years gained from the surgery.

make regular trips to Aravind to collaborate, learn from them,

and teach.

of expanding the Aravind approach to completely eliminate

cataract-related blindness and low vision throughout India.

While Aravind is recognized for excellence in clinical care,

The team projected the cost and corresponding benefit

in recent years it has expanded its footprint in clinical and

At a cost of $2.6 billion, surgery could be done on one eye of

health services research. For two years, the U-M Center for

each of the 30 million Indians affected. The resulting societal

Eye Policy and Innovation, one of the few ophthalmology

benefit is valued at $16 billion.

health services research programs in the world, has collaborated with Aravind on several projects.

Key findings

Aravind generates sufficient profit from a single paying

“This partnership benefits both parties,” says center direc-

tor and associate professor Joshua Stein, M.D., M.S. “Aravind

surgical patient to cover the cost of four patients who are

faculty members and trainees learn how to conduct health

unable to pay, with revenue left for infrastructure investment.

services research, clinical research, and clinical trials. We gain

The U-M study outlined a number of factors that contribute

a unique window into Aravind’s ability to manage and provide

to this remarkable formula:

quality eye care at low cost to so many patients.”

• Surgical skill. Each Aravind surgeon performs thousands

of procedures annually. “It’s humbling to see these excellent

In October 2016, a team including Kellogg researchers

Joshua Ehrlich, M.D., M.P.H., Alan Robin, M.D., Dr. Stein,

surgeons in action,” Dr. Ehrlich says.

and medical student Hong-Gam Le published, in the journal Health Affairs, their results generated through the KelloggAravind collaboration.

India’s Aravind Eye Care System performs more than 10,000 outpatient cataract surgeries a month in just one location, with some of the best outcomes in the world. How do they do it?

What can we learn from them?

12

Joshua Stein, M.D., M.S., professor of Ophthalmology (left), with Joshua Ehrlich, M.D., M.P.H., fellow in glaucoma

“Their complication rates are as low or lower than those found anywhere in the world. Seeing such difficult cases, as well as such a diversity of cases, prepares them to identify and counteract even the subtlest signs of complications.” Dr. Stein adds that

NIH R0-1 Research Grant Supports Personalized Care Models for Glaucoma and Ocular Hypertension

“their speed and agility also lessens the chance of introducing bacteria into the eye that can cause infection.”

• Standardized procedures. From pre-operative stage to recovery, every step is regimented, including checks and balances to ensure smooth operation.

• Monitored outcomes. Aravind’s leaders continually monitor each surgeon’s volume, complication rates, and intraocular lens measurement precision, investigating and resolving any deviation from quality standards.

• Strong institutional spirit and a commitment to excellence.

“The system thrives because everyone is able to work to his or her fullest potential,” Dr. Stein says. “Surgeons join Aravind for professional satisfaction and out of a desire to help others, not just for monetary gain.”

U-M School of Engineering professors Mark Van Oyen, Ph.D. and Mariel Lavieri, Ph.D. and Kellogg associate professor Joshua Stein, M.D., M.S. have been awarded $2.8 million from the National Institutes of Health Research Project Grant Program to pursue a novel approach to individualizing the care of patients with primary open-angle glaucoma and ocular hypertension.

Operating room at Aravind Eye Hospital, Madurai, India Lessons learned The study authors concede that some Aravind practices do not always conform to United States regulatory requirements, patient expectations, or cultural norms. For example, surgeons move from patient to patient in the same surgical suite without changing gloves or gowns between procedures. Interestingly, the rate of infection (endophthalmitis) is not increased because of this practice.

The authors assert that if volumes could be increased by

reducing time-consuming regulations without compromising quality, the Aravind model could have wider application for cataract surgery as well as for other high-volume, elective outpatient procedures like colonoscopy, vasectomy, or pacemaker insertion performed in developing and developed countries.

“To me, the biggest lesson learned is how relatively unnec-

essary regulatory hurdles can slow down efficiency and increase

The project will utilize National Eye Institute-funded clinical trial data to develop a decision support model to assist clinicians in four areas: 1.

Producing personalized forecasts of a patient’s probability of progressing from ocular hypertension (OHTN) to primary open-angle glaucoma (POAG) and from less severe to more advanced disease states

2. Determining the optimal timing to perform specific diagnostic tests to monitor each patient 3. Identifying patients at highest risk for irreversible vision loss due to POAG 4. Generating recommended target treatment goals for intraocular pressure for each patient The research team includes investigators from the University of Iowa, New York University, the University of California-San Diego, and Washington University in St. Louis.

costs,” Dr. Stein says. “And the second lesson is that volume matters.”

13

Pediatric Ophthalmology Update compared ROPtool with two other evaluation tools—remote reading of retinal images by either a trained lay reader or a panel of ROP experts. ROPtool was highly accurate.

Lay readers’ results also showed excellent sensitivity and

good specificity when compared to those of the experts. “Both options resulted in minimal false negatives,” Dr. Besirli says.

“That’s critically important for ROP diagnosis and treatment.”

This work confirms that telemedicine using proven

methods to read images remotely can help flag infants at risk and determine when they require bedside examination.

“We’re using telemedicine now to increase access to care for at-risk infants in hospitals across Michigan,” Dr. Besirli explains. “With telemedicine, Kellogg experts are able to consult remotely, which improves family-centered care by reducing the Cagri Besirli, M.D., assistant professor of Ophthalmology

From improving access to pediatric eye care in underserved United States communities to training pediatric ophthalmologists in China, Kellogg researchers are leading significant initiatives to improve children’s eye care. Much of their work is funded through a grant from the W.K. Kellogg Foundation.

Using Telemedicine to Monitor Retinopathy

Addressing Disparities in Diagnosing Strabismus As part of a 2016 study recently reported in the journal Ophthalmology, Kellogg researchers Joshua Ehrlich, M.D., M.P.H., Joshua Stein, M.D., M.S., Chris Andrews, Ph.D., Paul Lee, M.D., J.D., and David Musch, Ph.D., M.P.H. accessed a large insurance claims database to evaluate the extent of underdiagnosis of strabismus in Medicaid-insured children in Michigan and North Carolina.

“Diagnoses of strabismus were less likely among black

of Prematurity

children and among children living in poorer communities

Premature babies need screening for retinopathy of prematurity

a fellow in glaucoma. “Our findings reinforce the importance

(ROP) early and often. These babies require treatment within

of ensuring that children living in economically poorer areas

72 hours of diagnosis to prevent blindness. This is daunting

have access to the services of eye care professionals to prevent

standard for many rural communities and hospital neonatal

irreversible vision loss.”

intensive care units.

Stein, M.D., M.S. and colleagues at other universities was

Kellogg faculty and trainees are developing and evaluating

regardless of their race or ethnicity,” says Dr. Ehrlich, who is

A related U-M study led by associate professor Joshua

technological and telemedicine solutions that make it possible

published in the journal Health Affairs. It confirmed the

for doctors to make ROP diagnoses and treatment plans

underdiagnosis of both strabismus and amblyopia among

earlier and with greater confidence, even if the premature baby

children in less-affluent families. Using claims data for nearly

is far away.

900,000 insured children, the study found significantly lower

use of eye care services among children from poorer families.

Assistant professor Cagri Besirli, M.D., Ph.D. is using

new software called ROPtool to help determine whether

treatment is required. Developed at Duke University and the

13,000 strabismus and more than 5,000 amblyopia cases

University of North Carolina, ROPtool quantifies vascular

were not diagnosed over a 10-year period. Clearly, more

dilation and tortuosity from retinal images.

needs to be done to overcome the barriers that keep kids

from obtaining the eye care services they need.”

Dr. Besirli and collaborators at the University of Oregon,

Duke University, and William Beaumont Hospital in Detroit

14

need for patient transfers.”

“As a result,” says Dr. Stein “we estimate that nearly

Improving Pediatric Ophthalmology in China For most of his career, Professor Monte Del Monte, M.D. has been a leader in the American Association for Pediatric Ophthalmology and Strabismus (AAPOS). Since 2002, he has been instrumental in an AAPOS initiative to improve pediatric ophthalmology and strabismus in China, in part by developing a Western-style fellowship training program at the Tianjin Eye Hospital in Tianjin, China.

Prior to 2002, there were no formal graduate fellow-

ship programs in any medical specialty in China. Training in pediatric ophthalmology was accomplished largely through apprenticeships with self-trained physicians. AAPOS proposed developing postresidency training for Chinese pediatric ophthalDavid Musch, Ph.D., M.P.H., professor of Ophthalmology

Several Kellogg projects tackling disparities in pediatric eye care

mology subspecialists based on the format of AAPOS-approved fellowships in the United States.

“I was among several AAPOS members who began visiting

China regularly in 2008 to lecture, examine patients, and perform demonstration surgeries,” Dr. Del Monte recalls. “As the

are funded by a grant from the

fellowship collaboration was formalized, we selected one of the

W.K. Kellogg Foundation.

the program.”

Enhancing the Michigan Vision Screening Program

fellowship administration by completing a six-month observer

Professor David Musch, Ph.D., M.P.H. and collaborators

Dr. Del Monte returned to Tianjin Eye Hospital to provide

are looking out for the eye health of children in the state of Michigan, which mandates vision screening for all children before starting kindergarten and at intervals throughout elementary school. To increase the policy’s effectiveness, Dr. Musch and his colleagues have partnered with the Michigan Department of Health and Human Services (MDHHS), which administers the screening program.

The department uses the Titmus V3, a screening tool to

evaluate the sight of elementary students. Facing pressure to use

first fellows, Yeuping Li, M.D., to serve as the local director of

Dr. Li gained experience in patient care, surgery, and

fellowship at Kellogg in 2011. The following year, Dr. Li and other fellows with hands-on surgical training.

The AAPOS collaboration with Tianjin Eye Hospital

marks the first time a national subspecialty society has established a training curriculum in a developing country. “Today every significant ophthalmology department, hospital, and training program in China has a section of pediatric ophthalmology with dedicated subspecialists, in large part due to our efforts,” Dr. Del Monte explains.

the same tool with preschoolers, the MDHHS turned to Kellogg and local pediatric ophthalmologist John Baker, M.D. to help evaluate the idea.

“Our testing confirmed that current screening protocols

are better than Titmus V3 at detecting amblyopia and strabismus in preschoolers,” Dr. Musch says.

The next step is to take a closer look at how the state

responds to problems identified through screening. “Right now, more than 600,000 children are screened annually, and 10 percent require a follow-up exam,” Dr. Musch explains.

“We need better record keeping and better care practices

for children requiring follow-up to ensure they get the recommended exams.”

Dr. Musch is developing a demonstration project to

illustrate practical ways to enhance follow-up.

Professor Monte Del Monte in Tianjin, China, with Yeuping Li, M.D. (to his right), flanked by two Chinese fellowship trainees in pediatric ophthalmology 15

139 ,

0 136,60 61

101

Clinical Trials Update

6 201

1 01

2012

85

201 5

4 201

91

201 3

86

and treatment in addition to administrative office needs.

61

Tower into a one-stop destination for clinical trials. The research

72

with architects to transform an entire floor of the older Kellogg

2

66%

of assistant professor Grant Comer, M.D., M.S., who worked

center includes adaptable space for patient examinations, testing

2010

Opened in June 2015, the KCRC is under the direction

2009

Kellogg Clinical Research Center (KCRC).

61

93

08

growth rate over 10 years

Eye Center, are now centralized within the 5,500 square-foot

20

Faculty

Clinical trials, an active component of research at the Kellogg

59

2007

A critical part of the KCRC is its crew of five research

coordinators, including Karen King, the center’s research director, and Lindsay Godsey, Pamela Campbell, Munira Hussain,

trained ophthalmic technicians, they interact with patients

Sonal Trivedi, and James Greeen. They assume the major role

for testing and exams as well as scheduling and support. That

in conducting the trials, easing the burden for participating

builds stronger relationships,” she adds.

patients and faculty investigators.

focus more on the science and less on the administrative compo-

“The KCRC brings real advantages for study subjects,”

Dr. Comer pointed out that “by allowing Kellogg doctors to

Ms. King says. “They appreciate the quieter, more personalized

nents of research, the KCRC and our able cadre of coordinators

environment. And since our research coordinators are also

will make possible significant advances sooner rather than later.”

Kellogg Clinical Research Center coordinators James Greeen, Pamela Campbell, Karen King, and Lindsay Godsey. (Munira Hussain, Sonal Trivedi are not pictured.)

16

“

We developed the KCRC to maximize the impact of clinical research on those facing visually threatening diseases. By allowing Kellogg doctors to focus more on the science and less on the administrative

”

components of research, I’m confident that the KCRC will help us make significant advances sooner rather than later.

—Grant Comer, M.D., M.S.

KEC Clinical Studies The following is a snapshot of studies currently enrolling new patients at Kellogg. To see a full list of studies, visit kellogg.umich.edu/research/ kcrc.html

GENERAL IRB #HUM00072885 A comprehensive assessment of ocular telemedicine, including ophthalmic photographs, to test for eye disease.

A vision and eye care questionnaire identifies visual problems.

Principal investigator: Maria Woodward, M.D. Study contact: Elaine Lok (734) 936-8120 elok@med.umich.edu

CORNEA

GLAUCOMA

IRB #HUM00089615 A prospective, multicenter post-approval study of Visioncare’s implantable miniature telescope in patients with bilateral, severe to profound central-vision impairment associated with end-stage agerelated macular degeneration.

Principal investigator: Shahzad Mian, M.D. Study contact: Munira Hussain, (734) 647-8397 hussain@med.umich.edu

IRB #HUM00111521 A cross-sectional study of the prevalence of TGFBI corneal dystrophies in a North American population.

Principal investigator: Shahzad Mian, M.D. Study contact: Munira Hussain, (734) 647-8397 hussain@med.umich.edu

IRB #HUM00112614 A pilot test of the eyeGuide: This study will evaluate the impact of two personalized technology-based behavior-change programs that may help patients remember to take their glaucoma medication.

Principal investigator: Paula Anne Newman-Casey, M.D. Study contact: Laurie Taylor (734) 232-8057, laurieat@med.umich.edu IRB #HUM00095080 A test of the efficacy and safety of two dose strengths of sustained-release bimatoprost compared to treatment with timolol 0.5% eye drops in lowering eye pressure in patients with open-angle glaucoma or high eye pressure.

Principal investigator: Sayoko Moroi, M.D. Study contact: Munira Hussain (734) 647-8397, hussain@umich.edu

17

NEURO-OPHTHALMOLOGY

RETINA

IRB #HUM00114708 A phase II/III, randomized, doublemasked, sham-controlled trial of QPI1007 delivered by single- or multidose intravitreal injection(s) to subjects with acute nonarteritic anterior ischemic optic neuropathy.

Principal investigator: Lindsey De Lott, M.D.

IRB #HUM00072124 The development of a normative optical coherence tomography image database of healthy human retinas.

Volunteers with healthy eyes are being recruited.

Principal investigator: Thomas Gardner, M.D. Study contact: Katherine Joltikov joltikov@med.umich.edu

OCULAR ONCOLOGY IRB #HUM00082579 A test of vismodegib for orbital and periocular basal cell carcinoma following the treatment course for orbital BCCA with the oral medication vismodegib to determine whether it helps maintain functional vision and/or improves the function of the tear-drainage system.

Principal investigator: Alon Kahana, M.D., Ph.D. Study contact: Sonal Trivedi (734) 615-58560 strivedi@med.umich.edu

PEDIATRIC OPHTHALMOLOGY IRB #HUM00105702 An observational, multicenter study of the prevalence of cerebrotendinous xanthomatosis in patient populations diagnosed with early-onset idiopathic bilateral cataracts.

Principal investigator: Monte Del Monte, M.D. Study contact: Sonal Trivedi (734) 615-58560 strivedi@med.umich.edu

IRB #HUM00101130 The Periocular and Intravitreal Corticosteroids for Uveitic Macular Edema (POINT) trial: A study to evaluate three of the most commonly used treatments for uveitic macular edema: periocular triamcinolone, intravitreal triamcinolone and intravitreal dexamethasone implant.

Principal investigator: Susan Elner, M.D. Study contacts: Pamela Campbell (734) 936-0138 pamtitus@med.umich.edu Lindsay Godsey, (734) 936-9798 godseyli@med.umich.edu IRB #HUM00109572 Diabetic macular edema and midperipheral retina: A study to better understand the effect of diabetic retinopathy on visual function in hopes of improving screening and treatment.

Principal investigator: Thomas Gardner, M.D. Study contact: Katherine Joltikov, joltikov@med.umich.edu

From Clinical Trial to Outpatient Treatment

Corneal Cross-Linking Kellogg now offers corneal cross-linking, a new in-office treatment to stop progressive vision loss due to keratoconus and other disorders.

The procedure involves removing the front layer of the cornea and administering liquid riboflavin, a B vitamin, to the surface of the eye, which helps the cornea absorb ultraviolet light and stiffen. Ultraviolet light is then delivered at differing time intervals and intensity. This 90-minute treatment strengthens corneas weakened by keratoconus and other corneal diseases or by LASIK surgery.

Cross-linking was introduced at Kellogg on the basis of successful clinical trials conducted by professor Shahzad Mian, M.D. in collaboration with other ophthalmic institutions. Results of the trial, sponsored by Avedro, led the FDA to approve cross-linking for progressive keratoconus in mid-April 2016. “We can now offer a treatment that, if provided early in the disease, can help maintain better vision and reduce the need for corneal transplants,� Dr. Mian says.

18

IRB #HUM00099155 A study to compare perimetry techniques for identifying and monitoring early diabetic retinopathy.

Principal investigator: Thomas Gardner, M.D. Study contact: Katherine Joltikov joltikov@med.umich.edu IRB #HUM00118570 A study of the safety and efficacy of 2 mg abicipar pegol (AGN-150998) compared to 0.5 mg ranibizumab in treatment-naive patients with neovascular age-related macular degeneration.

Principal investigator: Grant Comer, M.D., M.S. IRB #HUM00060596 A study to characterize deficits in retinal structure and function among patients with proliferative diabetic retinopathy.

Principal investigator: Thomas Gardner, M.D. Study contact: Katherine Joltikov joltikov@med.umich.edu IRB #HUM00047124 A study to identify people with macular telangiectasia type 2 and their affected family members to create a registry for current and future research.

Principal investigator: Grant Comer, M.D., M.S.

Next Generation Report Card

Fluorescein angiogram (above) shows optic nerve and peripapillary hyperfluorescence; fundus photo (right) shows asteroid hyalosis and an inferior retinal detachment

include practitioners and interested learners everywhere,” says assistant professor

A new initiative is giving University of Michigan physicians easy online access to their individual quality metrics.

“Kellogg surgeons will be among the first to use next generation ‘report cards’ as part of the Kellogg Eye Center’s ongoing commitment to continuous improvement in quality and safety,” says associate professor Jennifer Weizer, M.D., director of the Kellogg quality assurance team.

Collecting and reporting volume and outcomes data is nothing new to the Kellogg Eye Center. But until now that information has been used by departments only on a summary basis. The new platform makes it possible for individual surgeons to view their own specific metrics at any time point and compare them to the overall performance of their department.

“The new system brings everything together under one umbrella,” Dr. Weizer says. “The simple online dashboard format gives doctors the timely information they need to set their own performance goals and find areas where they might be able to improve.”

To see Kellogg’s metrics for cataract surgery, corneal transplant, glaucoma care, oculoplastic surgery, refractive surgery, retinal detachment repair, and strabismus surgery, visit www.uofmhealth.org/

Thiran Jayasundera, M.D., developer and the other co-leader of the project. “Our

quality-safety/ophthalmology

Grand Rounds Finds a Broader Audience Presentations now summarized in convenient email format for smartphone and mobile devices A team of Kellogg faculty and staff have taken the weekly Ophthalmology Grand Rounds to the next level. Their idea: recap Grand Rounds presentations in an accessible summary format that can be delivered via email.

“We knew that the information our residents and trainees present would be

interesting and useful to many more people than were able to attend Grand Rounds in person,” says assistant professor co-leader of the project Christopher Gappy, M.D., who is involved in the project. “The challenge was to present the content so it could be read in a brief window of a clinician’s busy day.”

Faculty members, current residents, and Kellogg alumni began receiving

the emails in late spring, 2016. Examples of recent cases highlighted include a 73-year-old patient with pseudoexfoliation glaucoma and a six-year-old patient with congenital hereditary endothelial dystrophy.

“The feedback has been tremendously encouraging,” says program lead Dana

Schlegel, M.S., M.P.H., C.G.C. “Physicians on the distribution list tell us that they appreciate the variety of cases presented and the ability to follow up with the presenting physician to learn more. For presenting physicians, it’s an opportunity to share their clinical experiences and observations with a wider audience.”

“Based on the positive response, we're expanding the audience for the emails to

hope is that this will grow into an important continuing education resource for clinicians who may encounter such cases in their practices only infrequently, if at all.”

To sign up to receive Kellogg Eye Center Grand Rounds emails, visit

kellogg.umich.edu/email/grand-rounds-subscribe.html.

19

Kellogg’s Global Impact Showcased at International Night

More than 100 medical students and faculty members gathered on October 20, 2016, at the Kellogg Eye Center for International Ophthalmology’s fourth annual International Night.

This event, one of the largest yearly University of Michigan Medical School gatherings, brings global leaders in ophthalmology to Ann Arbor and highlights Kellogg’s clinical, educational, and

Dispatch from Down Under The 2016 event featured keynote speaker Hugh Taylor, M.D., president of the International Council of Ophthalmology and one of Australia’s foremost academic and policy leaders in eye

“Ophthalmology is one of the

health. Dr. Taylor’s career path has taken him far beyond his native Australia to pursue

research influence around the world.

most dynamic departments in the

research and clinical activities in the United

Medical School in the breadth and

Middle East. His early work with the World

Numerous Kellogg programs are in place

around the world in partnership with Global

States, Central America, West Africa, and the

REACH, the U-M Medical School’s platform

depth of global activities benefitting

Health Organization helped improve living

for international research, education, and

faculty as well as students

refugees who fled to Pakistan following the

clinical care collaborations.

“Ophthalmology is one of the most

dynamic departments in the Medical School in terms of the breadth and depth of global

conditions for more than 1.5 million Afghan

and trainees.”

1979 Soviet invasion.

— Joseph Kolars, M.D.

join the faculty of the University of Mel-

activities benefitting faculty as well as students and trainees,” says Joseph Kolars, M.D., senior associate dean for education and global initiatives and director of Global REACH.

Since returning to Australia in 1990 to bourne, much of Dr. Taylor’s energy has been

devoted to a cause he first encountered as a resident: preventing blindness among his homeland’s indigenous aboriginal communities. His research, education, and policy efforts have led to the virtual eradication of trachoma among the aborigines, reducing the prevalence of the disease from 20 percent to less than 5 percent.

Dr. Taylor’s contributions to global health and health

disparities research were recognized in 2001 with Australia’s highest honor for service to humanity, the Companion of the Order of Australia.

During his visit to Kellogg, Dr. Taylor also served as

scholar-in-residence, meeting with medical students, ophthalmology residents and fellows. He challenged U-M physicians in training to advocate for underserved populations with the same dedication and compassion they bring to the care of individual patients.

Assistant professor Scott Lawrence, M.D. describes his experience in Africa on International Night

20

“If you are interested in global health,” he points out,

“you should remember to think global but act local.”

Hugh Taylor, M.D., 2016 Kellogg International Scholar-in-Residence Geoffrey Thun, Ph.D., U-M associate professor of Architecture

David Sanders, M.D., M.P.H., second-year ophthalmology

Nita Valikodath, U-M fourth year medical student

with no professional or technical background to screen patients

resident, comments that “Dr. Taylor reminds me why I want

and prepare them for surgery.

to devote part of my career to international health.”

In addition to observing Aravind practices, Kellogg investi-

gators collaborate on studies and clinical trials at Aravind and Kellogg in India

in training practitioners in clinical and health services research.

In addition to the keynote address, International Night was an

Read more about one recent project on page 12.

opportunity to spotlight Kellogg’s impact on global eye health, including groundbreaking collaborations with U-M Global REACH in India and Jamaica.

Kellogg has forged a partnership with the Aravind Eye

Care System, India’s largest provider of eye care services. The relationship provides numerous learning opportunities for both partners.

At International Night, U-M fourth year medical student

Nita Valikodath reported on one aspect of Aravind’s remarkably efficient surgical model: a program that trains young women

Bringing the Michigan Difference to China

Yan He, M.D. (center), director of the eye bank at the Second Xiangya Hospital of Central South University in Changsha, China. She is pictured here in China with her husband Xiao Hu, M.D. and their 1-year old son Zitong Hu.

Kellogg in Jamaica This year, Kellogg faculty members, Medical School residents and trainees continued a commitment to improving eye health among people in Jamaica who are underserved. As part of a novel collaboration with U-M’s A. Alfred Taubman College of Architecture and Urban Planning, a multidisciplinary team converted a recycled shipping container into a fully functioning “eye clinic in a container” in the rural village of Sandy Bay, Jamaica.

Read more about the project on page 11.

Yan He, M.D. is on the ophthalmology faculty at Second Xiangya Hospital of Central South University in Changsha, China, where she directs its eye bank.

She was a research fellow at the Kellogg Eye Center from October 2012 to October 2013 under the mentorship of Kellogg professor H. Kaz Soong, M.D.

As a young ophthalmologist forming an interest in corneal diseases, Dr. He met Dr. Soong in 2010 when she was assigned as his guide at the 20th anniversary of the establishment of The Tongren Eye Bank, the first eye bank in China. Dr. Soong had been the leader in linking Tongren Hospital and the Michigan Eye-Bank (now called Eversight Michigan).

According to Dr. He, “there is a long wait for donated corneal tissue in China, because the body is considered a gift from one’s parents, so that organ donations are coming mostly from outside China.” But with the skills she learned at Kellogg, Dr. He is slowly transforming customs in her country—to include the Michigan difference!

21

Front row: Dina Farjo, Rafid Farjo, Paul Sieving, M.D., Ph.D., Muna Farjo, M.D., Ayad Farjo, M.D. Back row: Rand Farjo, M.D., Reem Farjo, Rafal Farjo, Ph.D., Anastas Farjo

Alumni Weekend 2016 The Kellogg Eye Center’s 22nd annual fall reunion weekend gave current and past students, fellows, trainees, and faculty members a chance to network, share best practices, and hear from leaders in ophthalmology whose successes trace back to Ann Arbor. Among the day’s activities were two invited lectureships.

The 2016 Farjo Lecturer: Paul A. Sieving, M.D., Ph.D. The Qais A. Farjo, M.D., Memorial Lectureship was endowed in 2015 in tribute to one of Kellogg’s most talented alumni. A tireless physician, surgeon, researcher, friend and mentor, Farjo lost his battle with cancer in 2014.

The 2016 Farjo lecture was offered by Paul A. Sieving,

M.D., Ph.D. Since 2001, Dr. Sieving has served as director of the National Eye Institute at the National Institutes of Health.

Prior to his appointment, Dr. Sieving spent 16 years as the Paul R. Lichter Professor of Ophthalmic Genetics at the University of Michigan, where he was the founding director of the U-M Center for Retinal and Macular Degeneration.

Dr. Sieving began his lecture by recalling the impact of U-M

ophthalmologist Harold Falls, M.D., who, in 1941, established one of the first human heredity clinics in the United States.

He has followed in Dr. Falls’ footsteps, beginning with

research at U-M in the 1980s. Dr. Sieving and his mentor E. Paul Geiser, M.D. developed the first mouse model of X-linked juvenile retinoschisis, a rare genetic disorder of the retina. He continues this work at the NIH, leading a Phase I/II human study of a therapeutic gene vector construct since 2015.

Dr. Sieving concluded his remarks by reflecting on what

Dr. Falls might have thought of this work. As early as the 1950s, 22

Dr. Falls published papers predicting that science would one day manipulate genes in order to improve eye health. “Now,” says Dr. Sieving, “70 years later, we know that to be correct.”

The 2016 Distinguished Alumnus Lecture: Michael R. Petersen, M.D., Ph.D.

The 2016 Distinguished Alumnus Lecture was given by Paul Sieving, M.D., Ph.D. (center), director of the National Eye Institute, flanked by Jonathan Trobe, M.D. (left) and Paul Lee, M.D., J.D. (right)

Michael Petersen, M.D., Ph.D., director of vitreoretinal services and immediate past chairman of the board of directors for the Cincinnati Eye Institute. Petersen’s lively remarks reminded the audience that in the course of every career, each experience

has value — and nothing learned ever goes to waste.

for evolving the Cincinnati Eye Institute from a family-owned

practice into one of the largest hybrid academic private practice

After earning his undergraduate degree at Western

During that time, Dr. Petersen was largely responsible

Michigan University, Dr. Petersen, a native of Saginaw,

groups of its kind in the country.

Michigan, pursued a Ph.D. in psychobiology at the University

of Michigan before joining the faculty at Indiana University.

job I never really sought,” leveraged not only his medical exper-

That transformation, which he describes as “a gargantuan

tise, but also many of the organizational skills he first learned managing labs at U-M and Indiana University. It required him to partner with business experts to restructure everything from hiring and retention to compensation and retirement policies. He described how he saw the institute through a period of drastic change in finances, detailing the transitions he and his associates made in the business model in order to keep the Institute solvent.

Today the CEI employs 48 ophthalmologists and 16 op-

tometrists. Its physicians perform more than 12,000 procedures annually in seven surgical suites.

Dr. Petersen closed his remarks with this advice: “The

lesson I hope to leave with my fellow Kellogg alumni is this: don’t be afraid to admit when you don’t know something.

"The lesson I hope to leave with my fellow Kellogg alumni is this:

Find partners whose talents complement your own, and you’ll succeed together.”

don’t be afraid to admit when you don’t know something.

Find partners whose talents complement your own, and you’ll succeed together."

—Michael R. Petersen, M.D., Ph.D.

Fascinated by the biological mechanisms of sensation and

perception, he decided to pursue a career in ophthalmology.

Following an accelerated medical school program at the University of Miami, Dr. Petersen returned to U-M for his internship and residency at Kellogg.

Following residency and fellowship training, he joined the

Cincinnati Eye Institute as its first retinal specialist, treating the full range of retinal diseases and disorders. He eventually assumed the post of chairman and managing partner, a post

Clinical instructors Shivani Kamat, M.D. (left), Philip Lieu, M.D. (center), and Bernadete Ayres, M.D., director of Ophthalmic Ultrasound

he held for 15 years.

23

“

John R. Breen (right) and his wife Jill, representing the Jerome Jacobson Foundation, with Paul Lichter, M.D., M.S.

Inaugural Jerome Jacobson Professorship and Research Fund will support glaucoma research

Dr. Sayoko Moroi Named Jerome Jacobson Professor In February 2016, the University of Michigan Medical School

apply these biomarkers during patient care to determine if they

named Sayoko Moroi, M.D., Ph.D., the inaugural Jerome

predict outcomes to specific medical therapies and the newer

Jacobson Professor of Ophthalmology and Visual Sciences.

glaucoma angle surgeries.”

Both the professorship and the Jerome Jacobson Vision Research

Fund were endowed to support glaucoma

Other active projects in Dr. Moroi’s lab include using detailed clinical measurements, tissue

research at the Kellogg Eye Center. Mr.

“It’s a privilege to care for patients, and

Jacobson had been a patient of Paul Lichter,

to work on their behalf in the research

to understand why a thin cornea predicts

former chair of the department.

lab. Investments in research like that

a pilot study of new head-mounted display

of the Jerome Jacobson Foundation are

technology used in retinitis pigmentosa and

her the opportunity to make an important

essential to reach our goal of preventing

ity, peripheral vision and quality of life.

advance in precision medicine— giving clini-

blindness and for developing cures for

M.D., professor of Ophthalmology and Dr. Moroi focuses on translational re-

search in glaucoma. The professorship gives

cians better tools for lowering eye pressure.

“Despite all our knowledge, we are

still limited to a trial-and-error approach to lowering eye pressure,” she notes.

eye diseases.”

biomechanics, genetics and bioinformatics glaucoma risk. Her team is also conducting

steroid-induced glaucoma to improve mobil“It’s a privilege to care for patients,” Dr. Moroi says, “and to work on their behalf in the research lab. Investments in

—Sayoko Moroi, M.D., Ph.D.

the type of research funded by the Jerome Jacobson Foundation are essential to reach

“Our multidisciplinary team is working to discover and validate

our goal of preventing blindness and developing cures for eye

genetic and structural biomarkers of aqueous production and

diseases. I am so grateful for their support.”

aqueous drainage. After validating such biomarkers, we will

24

”

Nancy Wheeler and Alma Wheeler Smith Albert Wheeler, Ph.D.

Wheeler Family Honors First African-American U-M Professor With Endowment A newly endowed glaucoma research fund honors the memory

of scientist and civil rights leader Albert Wheeler, Ph.D.

like he took everything else—as a battle to be fought,” added

Mary W. McDade, one of Wheeler’s daughters and an appellate

Dr. Wheeler was the first African-American professor at

“He was an extraordinary man, and he took glaucoma

the University of Michigan, accepting a tenure track position in

judge in Illinois.

1952. He held a master’s degree and Ph.D. from U-M’s School

of Public Health and spent his career in the departments of

gave him without fighting back. I know that he would be

microbiology and dermatology. He also was a tireless commu-

pleased about this gift and about the fact that it is accomplishing

“He was never one to lie down and take whatever life

nity leader who assisted individuals and worked locally, statewide and nationally to end segregation. With the help of

something for other people.”

“He was an extraordinary man, and he

Ms. McDade and her sisters Nancy Wheeler, a retired Washtenaw County judge,

Governor John Swainson and other dele-

took glaucoma like he took everything

gates at the early 1960s Michigan Constitu-

else as a battle to be fought.”

state senator and state representative, have

— Mary Wheeler McDade

Kellogg Eye Center in their father’s memory.

tional Convention, Dr. Wheeler wrote and achieved the enactment of the civil rights

and Alma Wheeler Smith, a former Michigan long supported glaucoma research at the

clause in the Michigan constitution. He was

Like her father, Nancy Wheeler has

elected the first and only African-American mayor of

glaucoma. “When I started experiencing the same things that

Ann Arbor, serving 1975 to 1977, and he and his wife, the

my father did, I began to realize that vision loss robs you of

late Emma Wheeler, helped found the local NAACP chapter.

your motivation because you can’t do what you used to do,”

He passed away in 1994 at the age of 78.

Wheeler says.

The Albert Wheeler Glaucoma Research Fund will be

She recalls that her father stopped driving, which he loved

established by amalgamating gifts from his family and a gift of

to do, and declined an opportunity to be a part of a national

$200,000 from the former Model Cities Health Clinic, founded

commission on AIDS. “Now I understand. Everything is more

by Emma Wheeler. The endowed fund will support research

difficult,” Wheeler says. “We want to support research so that

into glaucoma, a disease that caused Albert Wheeler’s sight to

people can be cured.”

diminish near the end of his life.

25

Ida Iacobucci, C.O. (left) and with Bruce Furr, C.O. in the Ida Lucy Iacobucci Orthoptic Clinic in the Kellogg Eye Center

Miss Ida ”

”

Honored for a Lifetime of Devotion to Kellogg Speaking with what friends call “her perpetual smile,”

and plans to support the orthoptic clinic by establishing a

associate professor Ida Lucy Iacobucci, C.O. accepted this

collegiate professorship with estate gifts.

year’s Lifetime Service Award at Kellogg’s 22nd annual

fall reunion event on September 30, 2016.

applauded Miss Iacobucci. Four of her closest colleagues spoke

of her contributions to the field.

“I am completely in awe at being honored for a position

At the award ceremony, alumni from across the country

that I deeply love— and having the privilege to serve for

almost 60 years,” she said.

adjunct clinical associate professor. “She is held in such high

regard and esteem.”

“Miss Ida,” as she is known by colleagues and patients,

“She is the queen of orthoptics,” said Gary Sandall, M.D.,

is one of the country’s leading orthoptists, a specialist in the

treatment of eye muscle problems. She joined the department

Ophthalmology, thanked Miss Iacobucci for her many years of

in 1957 to establish what is today the Ida Lucy Iacobucci

service to patients, pointing out that she helps even those with

Orthoptic Clinic. The clinic helps train orthoptic students

the most challenging strabismus and diplopia problems.

and residents, while evaluating and treating pediatric and

adult strabismus patients.

director of orthoptics, celebrated her quest to continue to be a

vital contributing member of the ophthalmology department.

She is the author of several groundbreaking journal articles,

Monte Del Monte, M.D., Skillman Professor of Pediatric

Bruce Furr, C.O., Ph.D., clinical assistant professor and

presents frequently at state and national meetings, and has

“You might wonder why Miss Ida still comes in to teach,”

received highest honors in her field. She recently updated the

queried professor Steven Archer, M.D., a longtime research

second edition of her book, “Clinical Approach to Ocular

collaborator of hers. “One reason is that the pediatric ophthal-

Motility: Characteristics and Orthoptic Management of Strabis-

mology section is family, and you don’t just retire from your

mus,” first published in 1980. She continues to lecture trainees

family.”

“Miss Ida” (center) with Bruce Furr, C.O. (far left), Gary Sandall, M.D. (left), Monte Del Monte, M.D. (right), and Steve Archer, M.D. (far right)

26

NE VICTORS FOR MICHIGAN MEDICINE UNIVERSITY OF MICHIGAN

MICHIGAN

Musson Family Helps Establish Legacy Fund Kenneth Musson, M.D. and his wife Patricia have joined their peers in establishing the Kellogg Alumni Legacy Fund, an umbrella fund that encourages annual gifts and bequests from alumni to benefit the educational mission of the Department of Ophthalmology and Visual Sciences.

The word “fortunate” comes up frequently in conversation

with Dr. Musson, who completed his residency in the department in 1969. He is thankful, he says, to have been accepted into the University of Michigan Medical School, deferring ophthalmology training until he completed his military service.

With lifelong connections to colleagues in Ann Arbor, Kenneth Musson, M.D. and Patricia Musson

Dr. Musson describes the department as “like a family. It’s a philosophy. You are part of our group. To this day, I have close ties. I don’t hear a lot of people speaking about other

programs in that way.”

Three other couples have made early commitments to the

Alumni Legacy Fund through annual giving and planned

To express their appreciation, the Mussons have generously

This effort is part of U-M’s Victors for Michigan campaign.

supported many department initiatives over the years, including

estate gifts: Richard Gutow, M.D., an alumnus who serves

endowed professorships honoring Drs. F. Bruce Fralick,

on Kellogg’s Victors for Michigan Campaign Leadership

Harold Falls, and Terry Bergstrom.

Council, and his wife, Susan; Paul Lichter, M.D., former

Money raised through this fund will

chair and founding director of the Kellogg

be used to make an unprecedented collec-

"We would not be where we are today

tive impact on the department’s ability to

without alumni who remain committed

Dr. Lee and his wife, Jennifer.

says Paul Lee, M.D., J.D., F. Bruce Fralick

to our success long after they complete

department are in respected academic

Professor and chair of the Department of

their residencies and fellowships.”

positions or successful private practices,”

—Paul Lee, M.D., J.D.,

mologist who has practiced in the Traverse

innovate and excel in all areas of its mission,

Ophthalmology and Visual Sciences.

“We would not be where we are today

without alumni who remain committed to

Eye Center, and his wife, Carolyn; and “A lot of people who trained in the

adds Dr. Musson, a comprehensive ophthalCity, Michigan, area for 47 years. “We give

our success long after they complete their residencies and

back out of gratitude. It is important to support the quality of

fellowships,” Dr. Lee says. “It is a privilege to partner with

the program and the institution and to provide a future for

them to advance education, research, and patient care for

the people who come after us.”

the next generations.”

To learn more, please call the Kellogg Eye Center development office at (734) 763-0875.

27

Meet Kellogg's New Faculty Laxmi Devisetty, M.D. Clinical Instructor Subspecialty: Retina and Uveitis Medical School: Rush Medical College (2006) Residency in Ophthalmology: Georgetown University (2010) Fellowship (Vitreoretinal Disorders): Associates in Ophthalmology, West Mifflin, PA (2012)

Philip Lieu, M.D. Clinical Instructor Subspecialty: Retina and Uveitis Medical School: University of Texas Southwestern Medical Center (2010) Residency in Ophthalmology: Texas Tech University (2014) Fellowship (Vitreoretinal Surgery and Diseases): Kresge Eye Institute, Wayne State University, (2016)

Shivani Kamat, M.D. Clinical Instructor Subspecialty: Glaucoma, Cataract, and Anterior Segment Disease Medical School: University of Florida College of Medicine (2010) Residency in Ophthalmology: Loyola University Medical Center (2014) Fellowship (Glaucoma): Massachusetts Eye and Ear Infirmary, Harvard University (2015)

Jill Schafer, O.D. Clinical Instructor School of Optometry: Ohio State University (2003)

Denise Kim, M.D. Clinical Instructor Subspecialty: Eye Plastic, Orbital and Facial Cosmetic Surgery Medical School: University of Michigan (2010) Residency in Ophthalmology: Kellogg Eye Center, University of Michigan (2014) Fellowship (Oculoplastics): Emory University (2016)

William Sray, M.D. Clinical Instructor Subspecialty: Comprehensive Ophthalmology and Cataract Surgery Medical School: Jefferson Medical College of Thomas Jefferson University (1991) Residency in Ophthalmology: National Naval Medical Center (1997) Fellowship (Cornea and External Disease): Wills Eye Institute, Thomas Jefferson University (2001)

Upcoming CME Programs Each year, Kellogg offers an informative series of continuing medical education programs designed to share new approaches to the diagnosis and management of eye disease across subspecialties. These are our upcoming programs: Saturday, May 13, 2017 89th Annual Spring Postgraduate Conference Pediatric Ophthalmology 8 a.m.– 5 p.m.

Kellogg Eye Center Ann Arbor, Michigan Friday, June 2, 2017 33rd Annual Research Day Friday, September 15, 2017 Fall Alumni Day 28

For more information or to register for these programs, visit: www.kellogg.umich.edu/education/cmeoverview.html For questions, contact Jennifer Burkheiser, CME Coordinator, at 734.763.2357 or kelloggCME@umich.edu.

2016 GRADUATING RESIDENTS

David Demill, M.D. Cornea Fellow Devers Eye Institute Portland, OR

Neil Farbman, M.D., J.D. Cornea Fellow University of California-Davis Eye Center, Sacramento, CA

Maxwell Stem, M.D. Retina Fellow Associated Retinal Consultants Royal Oak, MI

Michelle Kron-Gray, M.D., Ph.D. Graduate Chief Resident Kellogg Eye Center Ann Arbor, MI

Kevin Tozer, M.D. Cornea Fellow Minnesota Eye Consultants Bloomington, MN

Stephen Smith, M.D. Retina Fellow Stanford University Eye Clinic Palo Alto, CA

Grace Wang, M.D., Ph.D. Pediatric Ophthalmology Fellow Kellogg Eye Center Ann Arbor, MI

2016 GRADUATING CLINICAL FELLOWS

Smith Ann Chisholm, M.D. Pediatric Ophthalmology Medical College of Wisconsin Milwaukee, WI

Christopher Estopinal, M.D. Corneal and Refractive Surgery Virginia Eye Institute Richmond, VA

Devon Ghodasra, M.D. Retina, Uveitis, and Ocular Oncology Southeastern Retina Associates Chattanooga, TN

Yair Ivanir, M.D. Neuro-Ophthalmology Goldschleger Eye Institute Tel Aviv, Israel

Shannon Joseph, M.D., M.Sc. Eye Plastic and Orbital Surgery Wilmer Eye Institute, Johns Hopkins Baltimore, MD

Lisa Lagrou, M.D., M.Sc. Pediatric Ophthalmology University of Calgary Alberta, Canada

Metasebia Munie, M.D. Retina, Uveitis, and Ocular Oncology Mid Atlantic Permanente Medical Group Washington, DC

Melisa Nika, M.D. Glaucoma Vision Associates Toledo, OH

Thong Pham, M.D. Neuro-Ophthalmology Kentucky Lions Eye Center Louisville, KY

Morgan Renner, M.D., M.P.H. Glaucoma Acuity Eye Specialists Fullerton, CA

Andrew Reynolds, M.D. Pediatric Ophthalmology Ross Eye Institute Buffalo, NY

Meraf Wolle, M.D., M.P.H. Corneal and Refractive Surgery Wilmer Eye Institute, Johns Hopkins Baltimore, MD

29

2016 FIRST YEAR POST-DOCTORAL FELLOWS Swetha Jeganathan, M.Phil, M.AppMgt, P.G.Cert, F.H.E.A. Dr. Jeganathan works with Dr. Maria Woodward and Dr. Paula Anne NewmanCasey’s e-health team to investigate novel approaches to tele-ophthalmology, with the goal of translating ocular telemedicine research into clinical program development such as low cost technological devices. She grew up in Australia, and comes to Kellogg from the UK.

Enayat Nikoopour, Ph.D. Dr. Nikoopour is studying the immunopathology of autoimmune retinopathy in the laboratory of Dr. John Heckenlively. In his experiments, he is using genetically manipulated mice to study cellular and humoral immune responses to the retinal antigen Recoverin, as well as major immune cell checkpoints in the disease process. He comes to Kellogg from Western Ontario, Canada, and from Iran prior to that.

Ahmed Almazroa, Ph.D. Dr. Almazroa comes to Kellogg from Saudi Arabia. He is working with Dr. Sayoko E. Moroi to validate his glaucoma screening software for smartphones. He also has projects with Dr. Paul Carson in the Biomedical Engineering and Radiology departments which aim to develop a breast cancer screening system.

Andreia Goncalves, Ph.D. Dr. Goncalves joins Kellogg from Portugal.

She is working in Dr. David Antonetti’s laboratory, where she studies what contributes to the formation and loss of the blood-retinal barrier in normal vascular biology as well as in pathological conditions.

Navasuja Chandrasekaran, M.B.B.S., M.P.H. Dr. Chandrasekaran earned her medical degree in India, and most recently a masters in public health from the University of Michigan. She is currently working with Dr. Sayoko Moroi on a population-based study of women’s health across the nation (SWAN).

Bing Ross, Ph.D. Dr. Ross grew up in China, but most recently comes to Kellogg from Detroit’s Wayne State University. She works in the lab of Dr. David Zacks, focusing on the mechanism of photoreceptor cell death after retinal detachment.

Her goal is to find therapeutic treatments to prolong photoreceptor survival in order to postpone or prevent vision loss in patients with retinal detachment.

PAUL LEE APPOINTED TO U-M HEALTH SYSTEM BOARD Newly established board will advise the Regents and UMHS leadership.

30

Paul Lee, M.D., J.D., F. Bruce Fralick Professor and chair of the Department of Ophthalmology and Visual Sciences, was appointed in October 2016 to a one-year term on the U-M Health System board of directors.

Established in early 2016 to provide guidance to the Board of Regents and to UMHS leadership, the board will also act as a governing body for issues related to licensing, accreditation, compliance, and the quality of medical services.

Dr. Lee is one of four faculty members appointed to the board.

It also consists of four ex officio members: U-M President Mark Schlissel; Marschall S. Runge, M.D., Ph.D., executive vice president for medical affairs, CEO and dean of the U-M Medical School; Kevin Hegarty, U-M executive vice president and chief financial officer; and David Spahlinger, M.D., executive vice dean for clinical affairs and president of UMHS. Three health care and business leaders from outside U-M were also appointed.

FACULTY HONORS AND RECOGNITION

Steven F. Abcouwer, Ph.D. Editorial Board, American Journal of Physiology: Endocrinology & Metabolism Editorial Board, Journal of Clinical and Experimental Ophthalmology Editorial Board, Journal of Diabetic Research Grant Review Panel, American Diabetes Association Research Grant Reviewer, Diabetes Research Center Pilot and Feasibility Grant Program, Johns Hopkins University-University of Maryland Grant Reviewer, Diabetic Retinopathy Grants, Maratona da Saúde Prize, Portugal Grant Reviewer, Netherlands Organization for Scientific Research (NOW/ZonMw) Pre-Award Review Panel for Diabetes, Congressionally-Directed Department of Defense Peer Reviewed Medical Research Program Reviewer, Diabetes Complications Consortium Pilot and Feasibility Program, National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel, Diseases and Pathophysiology of the Visual System Member Conflict and R21 applications, National Eye Institute Special Emphasis Panel, Glaucoma, Retinopathy and Retinal Degeneration, National Eye Institute Special Emphasis Panel, Support of Competitive Research Program (SC1, SC2, SC3), National Eye Institute / National Institute of General Medical Sciences Study Section, Biology of the Visual System, National Eye Institute Study Section, Diseases and Pathophysiology of the Visual System, National Eye Institute

JULY 1, 2015 — SEPTEMBER 30, 2016

Monte A. Del Monte, M.D. (cont.)

Co-Sponsored Symposium on Pediatric Ophthalmology, 13th Middle East Africa Congress of Ophthalmology President, The Costenbader Pediatric Ophthalmology Society Section Chair, Pediatric Ophthalmology and Strabismus, American Academy of Ophthalmology Senior Consultant and Past Chair and, International Affairs Committee, American Association for Pediatric Ophthalmology and Strabismus Vice Chair, Fellowship Directors Committee, American Association for Pediatric Ophthalmology and Strabismus 12th Annual Robert D. Letson Lecturer in Pediatric Ophthalmology and Letson Visiting Professor Keynote Speaker in Pediatric Ophthalmology, Egyptian Ophthalmological Society

David A. Antonetti, Ph.D. Reviewing Editor, Diabetes

Patrice E. Fort, Ph.D., M.S. Editorial Board, Journal of Clinical and Experimental Ophthalmology Editorial Board, PlosOne Grant Reviewer, Diabetes Consortium Grant Reviewer, Project Grants on Diabetes Research, The National Research Funding Agency, The Maratona da Saúde Association, Portugal Grant Reviewer, Research Grant Review Committee, American Diabetes Association Grant Reviewer, Societal Challenges Grant Applications, French National Research Agency Grant Reviewer, Tender Offers Grant Applications, Insititu Carnat Voir et Entendre, Paris, France Study Section Ad-hoc Reviewer, Disease and Pathophysiology of the Visual System, National Eye Institute

Steven M. Archer, M.D. Senior Achievement Award, American Academy of Ophthalmology Richard G. Scobee Memorial Lecture, American Association of Certified Orthoptists Annual Meeting

Tom W. Gardner, M.D., M.S. Jules Gonin Prize, Club Jules Gonin, Retina Research Foundation Eva Kohner Lecture, European Association for the Study of Diabetes Eye Complications Group

Jill E. Bixler, M.D. Maintenance of Certification Committee, Comprehensive Section, American Academy of Ophthalmology

Peter F. Hitchcock, Ph.D. Academic Editor, PLoS One Co-organizer, NEI Audacious Goals Initiative ARVO Symposium

Theresa M. Cooney, M.D. Best Doctors in America Castle Connolly Top Doctor President-elect, Michigan Society of Eye Physicians and Surgeons

K. Thiran Jayasundera, M.D. Associate Editor, BioMed Central Ophthalmology U.S. Patent Awarded: U.S. Patent Application No. 14/493,712, Title: Systems and Methods for Diagnosing Inherited Retinal Diseases

Monte A. Del Monte, M.D. Best Doctors in America Castle Connolly Top Doctors US News and World Report Top Doctors Editorial Committee, Eye Wiki Online Encyclopedia, American Academy of Ophthalmology Grant Reviewer, Scientific and Grant Review Committee, Medical Advisory Board, Knights Templar Eye Research Foundation Grant Reviewer, Scientific Advisory Committee, National Priorities Research Program, Qatar National Research Fund Chair, American Association for Pediatric Ophthalmology and Strabismus

31

FACULTY HONORS AND RECOGNITION

Mark W. Johnson, M.D. Best Doctors in America Castle Connolly Top Doctor in Ophthalmology Ocular Surgery News Retina 150 Senior Honor Award, American Society of Retina Specialists Editorial Board, American Journal of Ophthalmology Editorial Board, Retina Credentials Committee, The Macula Society Member, Gass Club President, The Retina Society Founders Award and Lecture, Aspen Retinal Detachment Society, Aspen Keynote Speaker, New Mexico Academy of Ophthalmology Annual Scientific Meeting, Albuquerque Alon Kahana, M.D. Best Doctors in America US News and World Report Top Doctors Editorial Board, Ocular Surgery News Basic and Clinical Science Course Committee, Section 2, American Academy of Ophthalmology President, North American Society of Academic Orbital Surgeons Scientific Review Board, Alliance for Vision Research Study Section, National Eye Institute Thesis Committee Member, American Society of Ophthalmic Plastic and Reconstructive Surgeons U.S. Provisional Patent Application; Title: Lacrimal Stent with Opening Paul P. Lee, M.D., J.D. Best Doctors in America Castle Connolly Top Doctor US News and World Report Top Doctors Gold Fellow, Association for Research in Vision and Ophthalmology Editorial Board, Archives of Ophthalmology/JAMA Ophthalmology Board of Directors, Vice-Chair, and Chair-Elect, American Board of Ophthalmology Board of Directors, Association of University Professors of Ophthalmology Immediate Past Chair, ARVO Foundation External Advisory Board, Hoskins Foundation, American Academy of Ophthalmology Kenneth Swan Lecture, Casey Eye Institute, Oregon Health & Science University Pei-Fei Lee, Lecture, Massachusetts Eye and Ear, Harvard Medical School Roger P. Mason Lecture, National Medical Association, Detroit, MI Ronald J. Michels Lecture, Wilmer Eye Institute, Johns Hopkins University Paul R. Lichter, M.D., M.S. Best Doctors in America Castle Connolly Top Doctor US News and World Report Top Doctors Michael J. Lipson, O.D. Vice-President, Scleral Lens Education Society

32

JULY 1, 2015 — SEPTEMBER 30, 2016

Shahzad I. Mian, M.D. Best Doctors in America Castle Connolly Top Doctors Editorial Board, Cornea Guest Editor, Current Opinion of Ophthalmology Board of Directors, Cornea Society Board of Directors, Eye Bank Association of America Chair, Medical Advisory Council, Eversight Michigan Co-Chair, Accreditation Board, Eye Bank Association of America Co-Chair, Cornea Sub Day, American Academy of Ophthalmology Cornea Program Committee, American Academy of Ophthalmology Councilor, American Academy of Ophthalmology President-Elect, Program Directors Council, Association of University Professors in Ophthalmology Senior Medical Director, Eversight Michigan Vice Chair, Residency Review Committee, Accreditation Council for Graduate Medical Education Sayoko E. Moroi, M.D., Ph.D. Bioengineering of Neuroscience, Vision and Low Vision Technologies Study Section, Center for Scientific Review, National Institutes of Health Grant Review Committee, Eversight Michigan U.S. Provisional Patent Application No. 62/120,636; Title: Mapping of Internal Features on En Face Imagery U.S. Provisional Patent Application No. 62/209,543; Title: Technique for the Visualization and Analysis of Schlemm’s Canal and Collector Channel Ostia in the Human Aqueous Humor Outflow System David C. Musch, Ph.D. Editorial Board, JAMA Ophthalmology Editorial Board, Retina Editorial Board, Eye and Vision Joint Appointment, Professor, Department of Epidemiology, School of Public Health, University of Michigan Advisory Group, Cochrane Collaboration Eyes and Vision Group US Project Cataract Preferred Practice Patterns Panel, American Academy of Ophthalmology Cornea/External Disease Preferred Practice Patterns Panel, American Academy of Ophthalmology Grant Reviewer, Hong Kong Health and Medical Research Fund Methodologist, AAO Ophthalmic Technology Assessment Committee Methodologist, AAO Preferred Practice Patterns Committee Christine C. Nelson, M.D. Board of Directors, World Association of Eye Hospitals Co-Chair, Oculoplastics, International Council of Ophthalmology Member Subcommittee, Basic and Clinical Science Course, Section 7, American Academy of Ophthalmology Paula Anne Newman-Casey, M.D., M.S. Artemis Award, American Academy of Ophthalmology David L. Epstein, M.D. Clinician-Scientist Award, Chandler Grant Society National Representative, Alliance for Eye and Vision Research Emerging Vision Scientist Program

FACULTY HONORS AND RECOGNITION

Howard R. Petty, Ph.D. Specialty Chief Editor, Molecular Medicine, Frontiers in Cell and Developmental Biology U.S. Provisional Patent Application 62/343,464; Title: Biomarker Ratio Imaging Microscopy Donald G. Puro, M.D., Ph.D. Best Doctors in America Stein Innovation Award, Research to Prevent Blindness Rajesh C. Rao, M.D. Elected member, Macula Society Inaugural National Alliance for Eye and Vision Research Emerging Vision Scientist Leslie H. and Abigail S. Wexner Emerging Scholar, A. Alfred Taubman Medical Research Institute Young Investigator Award, Alcon Research Institute Class of 2011 Alumni Lecturer, Department of Ophthalmology, Harvard Medical School Annual Meeting and Alumni Reunion Julia E. Richards, Ph.D. Ad-hoc Study Section, Genes in Health and Disease Scientific Advisory Board, The Glaucoma Foundation Steering Committee, National Eye Institute Glaucoma Human Genetic Collaboration

JULY 1, 2015 — SEPTEMBER 30, 2016

Alan Sugar, M.D. Editor-in-Chief, Cornea Grant Reviewer, California Institute for Regenerative Medicine (www.cirm.ca.gov) Debra Thompson, Ph.D. Executive Editor, Experimental Eye Research Scientific Review Committee, Macular Degeneration Research, BrightFocus Foundation Sara Weidmayer, O.D. Regional Vice-Chair, Admittance Committee, American Academy of Optometry Kwoon Y. Wong, Ph.D. Carl Camras Translational Research Award, ARVO Foundation and Pfizer Ophthalmics William & Mary Greve Special Scholar Award, Research to Prevent Blindness Editorial Board, Current Eye Research Study Section, R01 Special Emphasis Panel Neurobiology of Visual Perception, National Institutes of Health Study Section, R01 Special Emphasis Panel Retinal Development, Signaling and Circuitry, National Institutes of Health U.S. Provisional Patent Application; Title: Mood-Enhancing Dynamic Commercial Lighting

Terry J. Smith, M.D. Distinguished Annual Lecture, Danish Endocrine Society Michael Smith-Wheelock, M.D. Best Doctors in America Joshua D. Stein, M.D., M.S. Editorial Board, JAMA Ophthalmology Advisory Panel, RAND Corporation CMS Cuts Task Force, American Glaucoma Society Director, AGS Cares Program, American Glaucoma Society GEMSSTAR Reviewer, National Institutes of Health IRIS Registry Analytics Task Force, American Academy of Ophthalmology Leadership Development Program, American Academy of Ophthalmology Standing Committee for Eye, Ear, Nose, and Throat, National Quality Forum Study Section, NEI Special Emphasis Panel, National Institutes of Health Vice Chair, Patient Care Committee, American Glaucoma Society U.S. Provisional Patent; Title: Magnetoelastic Actuator for Glaucoma Drainage Devices

33

FACULTY PUBLICATIONS JULY 1, 2015 — SEPTEMBER 30, 2016

Abbey AM, Besirli CG, Musch DC, Andrews CA, Capone A, Jr., Drenser KA, Wallace DK, Ostmo S, Chiang M, Lee PP, Trese MT. Evaluation of screening for retinopathy of prematurity by ROPtool or a lay reader.

Ophthalmology. 2016 Feb;123(2):385-90.

Al-Holou SN, Elner VM, Douglas RS, Joseph SS. Eyelid swelling and proptosis with systemic implications. Am J Med. 2016 Jul;129(7):e51-5.

Archer SM. The necessity of amblyopia.

Am Orthopt J. 2016;66(1):53-62.

Atkins SJ, Lentz SI, Fernando R, Smith TJ. Disrupted TSH receptor expression in female mouse lung fibroblasts alters subcellular IGF-1 receptor distribution. Endocrinology. 2015 Dec;156(12):4731-40.

Bailey JN‌ Lichter PR, Moroi SE, Richards JE, et al. Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma. Nat Genet. 2016 Feb;48(2):189-94.

Ballard TN, Briceno CA. Minocycline-induced orbital rim discoloration. J AAPOS. 2016 Apr;20(2):182-4.

Ballard TN, Elner VM, Briceno CA. Lower eyelid lesion. JAMA Ophthalmol. 2015 August;133(8):955-6.

Bansal S, Balakrishnan SA, Blachley T, Weizer JS, Lee PP, Stein JD. Subsequent receipt of interventions for glaucoma among a nationwide sample of patients who underwent laser peripheral iridotomy. Am J Ophthalmol. 2015 Aug;160(2):275-82.

Bar-Or A, Steinman L, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Smith TJ, Yeaman MR. Restoring immune tolerance in neuromyelitis optica: Part II. Neurol Neuroimmunol Neuroinflamm. 2016 Sept;3(5):e277.

Bavinger JC, DeLoss K, Mian SI. Scleral lens use in dry eye syndrome. Curr Opin Ophthalmol. 2015 Jul;26(4):319-24.

34

Bavinger JC, Dunbar GE, Stem MS, Blachley TS, Kwark L, Farsiu S, Jackson GR, Gardner TW. The effects of diabetic retinopathy and pan-retinal photocoagulation on photoreceptor cell function as assessed by dark adaptometry. Invest Ophthalmol Vis Sci. 2016 Jan;57(1):208-17.

Bennett LD, Wang YZ, Klein M, Pennesi ME, Jayasundera T, Birch DG. Structure/ psychophysical relationships in x-linked retinoschisis. Invest Ophthalmol Vis Sci. 2016 Feb;57(2):332-7.

Besirli CG. Retinal flecks in primary hyperoxaluria. JAMA Ophthalmol. 2015 Oct;133(10):e151532.

Bohnsack BL. Infantile-onset glaucoma and anterior megalophthalmos in osteogenesis imperfecta. J AAPOS. 2016 April;20(2):170-2.

Bolinger MT, Antonetti DA. Moving past anti-vegf: novel therapies for treating diabetic retinopathy. Int J Mol Sci. 2016 Sep;17(9):E1498.

Bollinger MT, Ramshekar A, Waldschmidt HV, Larsen SD, Bewley MC, Flanagan JM, Antonetti DA. Occludin S471 phosphorylation contributes to epithelial monolayer maturation. Mol Cell Biol. 2016 Jul;36(15):2051-66.

Boss JD, Shah CT, Elner VM, Hassan AS. Assessment of office-based practice patterns on protective eyewear counseling for patients with monocular vision. Ophthal Plast Reconstr Surg.

2015 Sep-Oct;31(5):361-3.

Bouffard MA, Cornblath WT, Rizzo JF, 3rd, Lee MS, DeLott LB, Eggenberger ER, Torun N. Transient monocular vision loss on awakening: a benign amaurotic phenomenon. J Neuroophthalmol. 2016 Sep 29 [Epub ahead of print].

Boynton GE, Raoof D, Niziol LM, Hussain M, Mian SI. Prospective randomized trial comparing efficacy of topical loteprednol etabonate 0.5% versus cyclosporine-a 0.05% for treatment of dry eye syndrome following hematopoietic stem cell transplantation. Cornea.

2015 Jul;34(7):725-32.

Breker DA, Stacey AW, Srinivasan A, Bursztyn LL, Trobe JD, Johnson MW. Vision loss caused by retinal and lateral geniculate nucleus infarction in H1N1 influenza.

J Neuro-ophthalmol. 2015 Sep;35(3):265-9.

Briceno CA, Elner VM, Demirci H. Lymphangiogenic and chemotactic factors in conjunctival melanoma. Ophthal Plast Reconstr Surg. 2015 Oct 12 [Epub ahead of print].

Briceno CA, Fuller ML, Bradley EA, Nelson CC. Assessment of the Abbreviated National Eye Institute Visual Function Questionnaire (NEI VFQ 9) in blepharoptosis and dermatochalasis.

Arq Bras Oftalmol. 2016 Jul-Aug;79(4):226-8.

Buena-Atienza E, Ruther K, Baumann B, Bergholz R, Birch D, De Baere E, Dollfus H, Greally MT, Gustavsson P, Hamel CP, Heckenlively JR, Leroy BP, Plomp AS, Pott JW, Rose K, Rosenberg T, Stark Z, Verheij JB, Weleber R, Zobor D, Weisschuh N, Kohl S, Wissinger B. De novo intrachromosomal gene conversion from OPN1MW to OPN1LW in the male germline results in Blue Cone Monochromacy. Sci Rep. 2016 Jun;6:28253.

Bursztyn LL, Belrose JC, Coupland SG, Fraser JA, Proulx AA. Remission of nonparaneoplastic autoimmune retinopathy after minimal steroid treatment. Retin Cases Brief Rep. 2015;9(2):173-6.

Callaghan BC, De Lott LB, Kerber KA, Burke JF, Skolarus LE. Neurology choosing wisely recommendations: 74 and growing. Neurol Clin Pract. 2015 Oct;5(5):439-47.

Campochiaro PA, Hafiz G, Mir TA, Scott AW, Sophie R, Shah SM, Ying HS, Lu L, Chen C, Campbell JP, Kherani S, Zimmer-Galler I, Wenick A, Han I, Paulus Y, Sodhi A, Wang G, Qian J. Pro-permeability factors after dexamethasone implant in retinal vein occlusion; the Ozurdex for Retinal Vein Occlusion (ORVO) Study. Am J Ophthalmol. 2015;160(2):313-321.

Cani AK, Soliman M, Hovelson DH, Liu CJ, McDaniel AS, Haller MJ, Bratley JV, Rahrig SE, Li Q, Briceno CA, Tomlins SA, Rao RC. Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies. Mod Pathol.

2016 Jul;29(7):685-97.

FACULTY PUBLICATIONS JULY 1, 2015 — SEPTEMBER 30, 2016

Carver KA, Yang D. N-acetylcysteine amide protects against oxidative stress-induced microparticle release from human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2016 Feb;57(2):360-71.

Choudhry N, Golding J, Manry MW, Rao RC. Ultra-widefield steering-based spectral-domain optical coherence tomography imaging of the retinal periphery. Ophthalmology. 2016 Jun;123(6):1368-74.

Castro V, Gardner TW. Evaluating changes in diabetic retinopathy: A case report illustrates how structural and functional assessments can be interpreted and correlated to provide a comprehensive patient evaluation. Retina Today. 2016 March;66-7.

Choudhry N, Golding J, Rao RC. Cataractous mountain on the corneal horizon: swept-source optical coherence tomography. Cataract Refract Surg. 2016 Jul;42(7):1097.

Castro-Navarro V, Odaibo SG, Ghodasra DH, Besirli CG. Bilateral BRVO in a patient with recurrent prostate cancer. BMJ Case Rep. 2015 Oct;212463.

Cestari DM, Gaier ED, Bouzika P, Blachley TS, De Lott LB, Rizzo JF, Wiggs JL, Kang JH, Pasquale LR, Stein JD. Demographic, systemic, and ocular factors associated with nonarteritic anterior ischemic optic neuropathy.

Ophthalmology. 2016 Sep 19 [Epub ahead of print].

Chawla B, Schley E, Williams AL, Bohnsack BL. Retinoic acid and pitx2 regulate early neural crest survival and migration in craniofacial and ocular development. Birth Defects Res B Dev Reprod Toxicol. 2016 Jun;107(3):126-36.

Chen JJ, Trobe JD. Optical coherence tomography should be used routinely to monitor patients with idiopathic intracranial hypertension. J Neuroophthalmol. 2016 Apr 12 [Epub ahead of print].

Chen L, Gage PJ. Heterozygous pitx2 null mice accurately recapitulate the ocular features of axenfeld-rieger syndrome and congenital glaucoma. Invest Ophthalmol Vis Sci. 2016 Sep;57(11):5023-30.

Chen L, Martino V, Dombkowski A, Williams T, West-Mays J, Gage PJ. AP-2beta is a downstream effector of pitx2 required to specify endothelium and establish angiogenic privilege during corneal development. Invest Ophthalmol Vis Sci. 2016 Mar;57(3):1072-81.

Chinskey ND, Rahimy E, Johnson MW. Acute macular neuroretinopathy following non-ocular trauma: a hypothesis regarding pathophysiologic mechanism. Ophthalmic Surg Lasers Imaging Retina. 2015 Nov-Dec;46(10):1013-20.

Choudhry N, Golding J, Rao RC. Seeing through walls: subhyaloid hemorrhage.

Ophthalmology. 2016 Jun;123(6):1172.

Choudhry N, Golding J, Rao RC. In the fold of a macular hole. Ophthalmology. 2016 Sep;123(9):1998.

Choudhry N, Rao RC. Enhanced depth imaging features of a choroidal macrovessel. Retin Cases Brief Rep. 2016 Winter;10(1):18-21.

Christopher KL, Elner VM, Demirci H. Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis.

Ophthal Plast Reconstr Surg. 2016 Aug 16 [Epub ahead of print].

Clark AJ, Coury EL, Meilhac AM, Petty HR. WO/Pt nanoparticles are NADPH oxidase biomimetics that mimic effector cells in vitro and in vivo. Nanotechnology. 2016 Feb;27(6):065101.

Clark AJ, Petty HR. WO3/Pt nanoparticles promote light-induced lipid peroxidation and lysosomal instability within tumor cells.

Nanotechnology. 2016 Feb;27(7):075103.

Clark AJ, Petty HR. Identification of lesion subtypes in biopsies of ductal carcinoma in situ of the breast using biomarker ratio imaging microscopy. Sci Rep. 2016 Jun;6:27039.

Cohen SR, Gardner TW. Diabetic retinopathy and diabetic macular edema. Dev Ophthalmol. 2016;55:137-46.

Coit P, De Lott LB, Nan B, Elner VM, Sawalha AH. DNA methylation analysis of the temporal artery microenvironment in giant cell arteritis. Ann Rheum Dis. 2016 Jun;75(6):1196-202.

Cunningham SI, Shi Y, Weiland JD, Falabella P, Olmos de Koo LC, Zacks DN, Tjan BS. Feasibility of structural and functional MRI acquisition with unpowered implants in Argus II retinal prosthesis patients: a case study. Transl Vis Sci Technol. 2015 Dec;4(6):6.

Custer PL, Fitzgerald ME, Herman DC, Lee PP, Cowan CL, Cantor LB, Bartley GB. Building a culture of safety in ophthalmology. Ophthalmology. 2016 Sep;123(9 Suppl):S40-5.

Davila JR, Mian SI. Infectious keratitis after keratoplasty. Curr Opin Ophthalmol. 2016 Jul;27(4):358-66.

Davis SW, Mortensen AH, Keisler JL, Zacharias AL, Gage PJ, Yamamura K, Camper SA. Beta-catenin is required in the neural crest and mesencephalon for pituitary gland organogenesis. BMC Dev Biol. 2016 May;16(1):16.

De Lott LB, Burke JF, Kerber KA, Skolarus LE, Callaghan BC. Medicare Part D payments for neurologist-prescribed drugs. Neurology. 2016 Apr;86(16):1491-8.

Dedania VS, Bakri SJ. Novel pharmacotherapies in diabetic retinopathy. Middle East Afr J Ophthalmol. 2015;22(2):164-73.

Dedania VS, Bakri SJ. Systemic safety of intravitreal anti-vascular endothelial growth factor agents in age-related macular degeneration. Curr Opin Ophthalmol. 2016;27(3): 224-43.

Dedania VS, Ghodasra DH, Kay CN, Roseman R, Johnson MW. Ciliochoroidal effusion and acute macular neuroretinopathy associated with cervical traction therapy. Retin Cases Brief Rep. 2016 Sep 23 [Epub ahead of print].

Dedania VS, Grob S, Zhang K, Bakri SJ. Pharmacogenomics of response to anti-VEGF therapy in exudative age-related macular degeneration. Retina. 2015;35(3):381-91.

Dedania VS, Hale BP, Bhatnagar P. Endogenous endophthalmitis due to clinically vancomycin-resistant Staphylococcus aureus.

Retin Cases Brief Rep. 2015;9(1):59-60.

35

FACULTY PUBLICATIONS JULY 1, 2015 — SEPTEMBER 30, 2016

DeLoss KS, Le HG, Gire A, Chiu GB, Jacobs DS, Carrasquillo KG. PROSE treatment for ocular chronic graft-versus-host disease as a clinical network expands. Eye Contact Lens.

2016 Jul;42(4):262-6.

Ehrlich JR, Spaeth GL, Carlozzi NE, Lee PP. Patient-centered outcome measures to assess functioning in randomized controlled trials of low-vision rehabilitation: a review. Patient.

2016 Aug 5 [Epub ahead of print].

DeMill DL, Hussain M, Pop-Busui R, Shtein RM. Ocular surface disease in patients with diabetic peripheral neuropathy. Br J Ophthalmol. 2015 Oct 23 [Epub ahead of print].

Elam AR, Blachley TS, Stein JD. Geographic variation in the use of diagnostic testing of patients with newly diagnosed open-angle glaucoma. Ophthalmology. 2016 Mar;123(3):522-31.

Demirci H, Elner VM. Contemplating the diagnostic certainty of primary iris mucosaassociated lymphoid tissue lymphoma.

JAMA Ophthalmol. 2015 Aug;133(8):970.

Demirci H, Kauh CY, Rajaii F, Elner VM. Intralesional rituximab for the treatment of recurrent ocular adnexal lymphoma. Ophthal Plast Reconstr Surg. 2016 Mar 4 [Epub ahead of print].

Demirci H, Worden F, Nelson CC, Elner VM, Kahana A. Efficacy of vismodegib (erivedge) for basal cell carcinoma involving the orbit and periocular area. Ophthal Plast Reconstr Surg. 2015 Nov-Dec;31(6):463-6.

Dixon MW, Besirli CG. Ethics of placebo procedures in ophthalmic surgical trials.

JAMA Ophthalmol. 2016 Jan;134(1):11-2.

Dulle JE, Fort PE. Crystallins and neuroinflammation: the glial side of the story. Biochim Biophys Acta. 2016 Jan;1860(1 Pt B):278-86.

Duncan JL, Biswas P, Kozak I, Navani M, Syed R, Soudry S, Menghini M, Caruso RC, Jeffrey BG, Heckenlively JR, Reddy GB, Lee P, Roorda A, Ayyagari R. Ocular phenotype of a family with FAM161A-associated retinal degeneration. Ophthalmic Genet. 2016 Mar;37(1):44-52.

Ehrlich JR, Anthopolos R, Tootoo J, Andrews CA, Miranda ML, Lee PP, Musch DC, Stein JD. Assessing geographic variation in strabismus diagnosis among children enrolled in Medicaid. Ophthalmology. 2016 Sep;123(9):2013-22.

Ehrlich JR, Kourgialis N, Friedman DS. Impaired visual acuity and spectacle ownership of urban migrant children in eastern China.

JAMA Ophthalmol. 2015;133(12):1406-7.

36

Estopinal CB, Ewald MD. Geographic disparities in the etiology of bacterial and fungal keratitis in the United States of America.

Semin Ophthalmol. 2016 April;31(4):345-52.

Estopinal CB, Mian SI. LASIK flap: postoperative complications. Int Ophthalmol Clin.

2016 Spring;56(2):67-81.

Fahim AT, Daiger SP. The role of X-chromosome inactivation in retinal development and disease. Adv Exp Med Biol.

2016;854:325-31.

Fahim AT, Simunovic MP, Mammo Z, Mitry D, Pakzad-Vaezi K, Bradley P, Mahroo OA. Comparison of ophthalmic training in 6 English-speaking countries. Can J Ophthalmol.

2016;51(3):212-8.

Feder RS, Olsen TW, Prum BE, Jr., Summers CG, Olson RJ, Williams RD, Musch DC. Comprehensive adult medical eye evaluation preferred practice pattern guidelines. Ophthalmology. 2016 Jan;123(1):P209-36.

Fox AR, Gordon LK, Heckenlively JR, Davis JL, Goldstein DA, Lowder CY, Nussenblatt RB, Butler NJ, Dalal M, Jayasundera T, Smith WM, Lee RW, Adamus G, Chan CC, Hooks JJ, Morgans CW, Detrick B, Sen HN. Consensus on the diagnosis and management of nonparaneoplastic autoimmune retinopathy using a modified Delphi approach. Am J Ophthalmol.

2016 Aug;168:183-90.

Fritsche LG, Igl W, Bailey JN‌ Branham KE, Heckenlively JR, Othman MI, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet.

2016 Feb;48(2):134-43.

Frohm ML, Griffith KA, Harms KL, Hayman JA, Fullen DR, Nelson CC, Wong SL, Schwartz JL, Bichakjian CK. Recurrence and survival in patients with Merkel cell carcinoma undergoing surgery without adjuvant radiation therapy to the primary site. JAMA Dermatol. 2016 Sep;152(9):1001-7.

Gage PJ, Hurd EA, Martin DM. Mouse models for the dissection of CHD7 functions in eye development and the molecular basis for ocular defects in CHARGE syndrome. Invest Ophthalmol Vis Sci. 2015 Dec;56(13):7923-30.

Gardner TW, Abcouwer SF, Losiewicz MK, Fort PE. Phosphatase control of 4E-BP1 phosphorylation state is central for glycolytic regulation of retinal protein synthesis. Am J Physiol Endocrinol Metab. 2015 Sep;309(6):E546-56.

Gardner TW, Chew EY. Future opportunities in diabetic retinopathy research. Curr Opin Endocrinol Diabetes Obes. 2016 Apr;23(2):91-6.

Ghodasra DH, Besirli C. Posterior polar annular choroidal dystrophy. JAMA Ophthalmol.

2015 Dec;133(12):e152148.

Ghodasra DH, Chen A, Arevalo JF, Birch DG, Branham K, Coley B, Dagnelie G, de Juan E, Devenyi RG, Dorn JD, Fisher A, Geruschat DR, Gregori NZ, Greenberg RJ, Hahn P, Ho AC, Howson A, Huang SS, Iezzi R, Khan N, Lam BL, Lim JI, Locke KG, Markowitz M, Ripley AM, Rankin M, Schimitzek H, Tripp F, Weiland JD, Yan J, Zacks DN, Jayasundera KT. Worldwide Argus II implantation: recommendations to optimize patient outcomes.

BMC Ophthalmol. 2016 May;16(1):52.

Ghodasra DH, Demirci H. Photodynamic therapy for choroidal metastasis. Am J Ophthalmol. 2016 Jan;161:104-9.

Ghodasra DH, Fante R, Gardner TW, Langue M, Niziol LM, Besirli C, Cohen SR, Dedania VS, Demirci H, Jain N, Jayasundera KT, Johnson MW, Kalyani PS, Rao RC, Zacks DN, Sundstrom JM. Safety and feasibility of quantitative multiplexed cytokine analysis from office-based vitreous aspiration. Invest Ophthalmol Vis Sci. 2016 Jun;57(7):3017-23.

FACULTY PUBLICATIONS JULY 1, 2015 — SEPTEMBER 30, 2016

Ghodasra DH, Katowitz JA, Liu GT, Binenbaum G. Indirect internal carotid-cavernous fistula in infancy. J Pediatr Ophthalmol Strabismus. 2015;52:e11-3.

Goncalves A, Lin CM, Muthusamy A, Fontes-Ribeiro C, Ambrosio AF, Abcouwer SF, Fernandes R, Antonetti DA. Protective effect of a GLP-1 analog on ischemia-reperfusion induced blood-retinal barrier breakdown and inflammation. Invest Ophthalmol Vis Sci. 2016 May;57(6):2584-92.

Gray EJ, Gardner TW. Retinal failure in diabetes: a feature of retinal sensory neuropathy. Curr Diab Rep. 2015 Dec;15(12):107.

Grubbs JR, Jr., Mian SI. Advising students interested in ophthalmology: a summary of the evidence. Ophthalmology.

2016 Jul;123(7):1406-10.

Grubbs J, Jr., Trobe JD, Fisher-Hubbard A. Opsoclonus-myoclonus syndrome in primary central nervous system lymphoma. J Neuroophthalmol. 2016 Mar 25 [Epub ahead of print].

Gupta D, Musch DC, Niziol LM, Chen PP. Refusal of surgical treatment for the fellow eye in Collaborative Initial Glaucoma Treatment Study (CIGTS) participants. Am J Ophthalmol.

2016 Jun;166:1-7.

Han DP, McKenney KC, Kim JE, Weinberg DV, Musch DC, Singh RS. Clinical evaluation of the rapid access vitreal injection guide: a handheld instrument for assisting intravitreal injections. Retina. 2016 Aug 2 [Epub ahead of print].

Helm JE, Lavieri MS, Van Oyen MP, Stein JD, Musch DC. Dynamic forecasting and control algorithms of glaucoma progression for clinician decision support. Operations Res. 2015 Sept/Oct;63(5):979-99.

Hood CT. Complications of intracorneal implants in refractive surgery. Int Ophthalmol Clin. 2016 Spring;56(2):155-61.

Hu Z, Liu Q, Paulus YM. New frontiers in retinal imaging. Int J Ophthalmic Res. 2016 Sep;2(3):148-58.

Hu Z, Wang X, Liu Q, Paulus YM. Photoacoustic imaging in ophthalmology. Int J Ophthalmol Eye Res. 2015 Sep;3(8):126-32.

Imai H, Misra GP, Wu L, Janagam DR, Gardner TW, Lowe TL. Subconjunctivally implanted hydrogels for sustained insulin release to reduce retinal cell apoptosis in diabetic rats. Invest Ophthalmol Vis Sci. 2015 Dec;56(13):7839-46.

Joseph SS, Joseph AW, Douglas RS, Massry GG. Periocular reconstruction in patients with facial paralysis. Otolaryngol Clin North Am. 2016 Apr;49(2):475-87.

Joseph SS, Yentz SE, Mikkilineni S, Nelson C, Kalemkerian GP. Eyelid metastasis in nonsmall cell lung cancer: diagnosis and management. Am J Med. 2016 Sep;129(9):e169-72.

Kamat SS, Gregory MS, Pasquale LR. The role of the immune system in glaucoma: bridging the divide between immune mechanisms in experimental glaucoma and the human disease. Semin Ophthalmol. 2016 Mar;31(1-2):147-54.

Katz DM, Trobe JD. Is there treatment for nonarteritic anterior ischemic optic neuropathy.

Curr Opin Ophthalmol. 2015 Nov;26(6): 458-63.

Kauh CY, Blachley TS, Lichter PR, Lee PP, Stein JD. Geographic variation in the rate and timing of cataract surgery among U.S. communities. JAMA Ophthalmol. 2016 Mar;134(3):267-76.

Kauh CY, Bursztyn LL. Positive apraclonidine test in Horner syndrome caused by thalamic hemorrhage. J Neuroophthalmol. 2015 Sep;35(3):287-8.

Kauh CY, Gupta S, Douglas RS, Elner VM, Nelson CC, Niziol LM, Kahana A. Compressive optic neuropathy and repeat orbital decompression: a case series. Ophthal Plast Reconstr Surg. 2015 Sep-Oct;31(5):385-90.

Khalsa SS, Hollon TC, Shastri R, Trobe JD, Gemmete JJ, Pandey AS. Spontaneous subarachnoid hemorrhage due to ruptured cavernous internal carotid artery aneurysm after medical prolactinoma treatment. BMJ Case Rep. 2016 June 15 [Epub ahead of print] Khan M, Rao PK, Rao RC. A brushfire in the eye. BMJ. 2016 Jun;353:i3075.

Khan M, Walters LL, Li Q, Thomas DG, Miller JM, Zhang Q, Sciallis AP, Liu Y, Dlouhy BJ, Fort PE, Archer SM, Demirci H, Dou Y, Rao RC. Characterization and pharmacologic targeting of EZH2, a fetal retinal protein and epigenetic regulator, in human retinoblastoma.

Lab Invest. 2015 Nov;95(11):1278-90.

Khawaja AP… Lichter PR, Moroi SE, Richards JE, et al. Assessing the association of mitochondrial genetic variation with primary open-angle glaucoma using gene-set analyses. Invest Ophthalmol Vis Sci. 2016 Sep;57(11):5046-52.

Kiang L, Johnson MW. Formation of an intraretinal fluid barrier in cavitary optic disc maculopathy. Am J Ophthalmol. 2016 Sep 30 [Epub ahead of print].

Kim DS, Korgavkar K, Zahid S, De Lott L, Prabhakar A, Foerster BR, Besirli CG. Vision loss after central retinal artery occlusion secondary to orbital sarcoid mass. Ophthal Plast Reconstr Surg. 2016 Mar-Apr;32(2):e37-40.

Klionsky DJ… Kahana A, Zacks DN, et al.

Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy.

2016;12(1):1-222.

Kochar B, Shan SJ, Anand G, Zinreich SJ, Gelber AC. Totally one-sided: painless unilateral proptosis. Am J Med. 2015;128(4):361-3.

Komaromy AM, Abrams KL, Heckenlively JR, Lundy SK, Maggs DJ, Leeth CM, MohanKumar PS, Petersen-Jones SM, Serreze DV, van der Woerdt A. Sudden acquired retinal degeneration syndrome (SARDS) - a review and proposed strategies toward a better understanding of pathogenesis, early diagnosis, and therapy.

Vet Ophthalmol. 2016 Jul;19(4):310-31.

37

FACULTY PUBLICATIONS JULY 1, 2015 — SEPTEMBER 30, 2016

Kong D, Gong L, Arnold E, Shanmugam S, Fort PE, Gardner TW, Abcouwer SF. Insulin-like growth factor 1 rescues R28 retinal neurons from apoptotic death through ERKmediated BimEL phosphorylation independent of AKT. Exp Eye Res. 2016 Aug;151:82-95.

Lin HC, Stein JD, Nan B, Childers D, Newman-Casey PA, Thompson DA, Richards JE. Association of geroprotective effects of metformin and risk of open-angle glaucoma in persons with diabetes mellitus.

JAMA Ophthalmol. 2015 Aug;133(8):915-23.

Korot E, Comer G, Steffens T, Antonetti DA. Algorithm for the measure of vitreous hyperreflective foci in optical coherence tomographic scans of patients with diabetic macular edema.

JAMA Ophthalmol. 2016 Jan;134(1):15-20.

Lipson MJ, Sandall G. Myopia control: science or luck. Eye Contact Lens. 2016 Jan;42(1):80-1.

Kothary PC, Rossi B, Del Monte MA. Valproic acid induced human retinal pigment epithelial cell death as well as its survival after hydrogen peroxide damage is mediated by p38 kinase.

Adv Exp Med Biol. 2016;854:765-72.

Kremer S… Smith TJ, et al. Use of advanced magnetic resonance imaging techniques in neuromyelitis optica spectrum disorder. JAMA Neurol. 2015 Jul;72(7):815-22.

Lagina A. Beware of the biofilm. Rev Cornea Contact Lens. 2016 Sep:14-7.

Lagina AL. Soft contact lens optimizes visual goals for a patient with keratoectasia. Optom Vis Sci. 2015 Nov;92(11):e409-13.

Lee P. Visual acuity screening among asymptomatic older adults. JAMA. 2016 Mar;315(9):875-6.

Lee WB, Shtein RM, Kaufman SC, Deng SX, Rosenblatt MI. Boston keratoprosthesis: outcomes and complications: a report by the American Academy of Ophthalmology.

Ophthalmology. 2015 Jul;122(7):1504-11.

Lertakyamanee P, Srinivasan A, De Lott LB, Trobe JD. Papilledema and vision loss caused by jugular paragangliomas. J Neuroophthalmol. 2015 Dec;35(4):364-70.

Li Z… Moroi SE, Richards JE, et al. A common variant near TGFBR3 is associated with primary open angle glaucoma. Hum Mol Genet. 2015 Jul;24(13):3880-92.

Lichter PR. Physician-industry interactions and anti-vascular endothelial growth factor use among US ophthalmologists. JAMA Ophthalmol. 2016 Aug;134(8):903-4.

38

Liu H, Tang J, Du Y, Lee CA, Golczak M, Muthusamy A, Antonetti DA, Veenstra AA, Amengual J, Von Lintig J, Palczewski K, Kern TS. Retinylamine benefits early diabetic retinopathy in mice. J Biol Chem. 2015 Aug;290(35):21568-79.

Liu X, Dreffs A, Diaz-Coranguez M, Runkle EA, Gardner TW, Chiodo VA, Hauswirth WW, Antonetti DA. Occludin S490 phosphorylation regulates vascular endothelial growth factor-induced retinal neovascularization.

Am J Pathol. 2016 Sep;186(9):2486-99.

Liu Y… Lichter P, Moroi SE, Richards JE, et al. A common variant in MIR182 is associated with primary open-angle glaucoma in the NEIGHBORHOOD consortium. Invest Ophthalmol Vis Sci. 2016 Aug;57(10):3974-81.

Lott ME, Slocomb JE, Gao Z, Gabbay RA, Quillen D, Gardner TW, Bettermann K. Impaired coronary and retinal vasomotor function to hyperoxia in individuals with type 2 diabetes. Microvasc Res. 2015 Sep;101:1-7.

Marcet MM, Shtein RM, Bradley EA, Deng SX, Meyer DR, Bilyk JR, Yen MT, Lee WB, Mawn LA. Safety and efficacy of lacrimal drainage system plugs for dry eye syndrome: a report by the American Academy of Ophthalmology. Ophthalmology. 2015 Aug;122(8):1681-7.

Marshall J, Wong KY, Rupasinghe CN, Tiwari R, Zhao X, Berberoglu ED, Sinkler C, Liu J, Lee I, Parang K, Spaller MR, Huttemann M, Goebel DJ. Inhibition of N-methyl-D-aspartate-induced retinal neuronal death by polyarginine peptides is linked to the attenuation of stress-induced hyperpolarization of the inner mitochondrial membrane potential. J Biol Chem. 2015 Sep;290(36):22030-48.

Melamed E… Smith TJ, et al. Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015 Jul;2(4):e134.

Mester T, Raychaudhuri N, Gillespie EF, Chen H, Smith TJ, Douglas RS. CD40 expression in fibrocytes is induced by tsh: potential synergistic immune activation.

PLoS One. 2016 Sep;11(9):e0162994.

Mian SI. Evaporative dry eye disease: promising new approaches for diagnosis and treatment. Curr Opin Ophthalmol. 2015 Jul;26(4):288.

Mian SI, De la Parra-Colín P, De Melo-Franco R, Johnson C, Barrientos-Gutierrez T. Dry eye disease incidence associated with chronic graft-versus-host disease: nonconcurrent cohort study (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2015 Sep;113:T11-1.

Multicenter Uveitis Steroid Treament (MUST) Trial Follow-up Study Research Group… Elner SG. Quality of life and risks associated with systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, or panuveitis: fifty-four-month results of the multicenter uveitis steroid treatment trial and follow-up study.

Ophthalmology. 2015 Oct;122(10):1976-86.

Nagia L, Lemos J, Abusamra K, Cornblath WT, Eggenberger ER. Prognosis of ocular myasthenia gravis: retrospective multicenter analysis. Ophthalmology. 2015 Jul;122(7):1517-21.

Newman-Casey PA, Blachley T, Lee PP, Heisler M, Farris KB, Stein JD. Patterns of glaucoma medication adherence over four years of follow-up. Ophthalmology. 2015 Oct;122(10):2010-21.

Newman-Casey PA, Dayno M, Robin AL. Systematic review of educational interventions to improve glaucoma medication adherence: an update in 2015. Exp Rev Ophthalmol.

2016 Jan;11(1):5-20.

Newman-Casey PA, Ravilla S, Haripriya A, Palanichamy V, Pillai M, Balakrishnan V, Robin AL. The effect of counseling on cataract patient knowledge, decisional conflict, and satisfaction. Ophthalmic Epidemiol. 2015 Dec;22(6):387-93.

FACULTY PUBLICATIONS

JULY 1, 2015 — SEPTEMBER 30, 2016

Newman-Casey PA, Robin AL, Blachley T, Farris K, Heisler M, Resnicow K, Lee PP. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015 July;122(7):1308-16.

Paulus YM, Cheng S, Karth PA, Leng T. Prospective trial of endogenous fungal endophthalmitis and chorioretinitis rates, clinical course, and outcomes in patients with fungemia. Retina. 2016 Jul;36(7):1357-63.

Puro DG, Kohmoto R, Fujita Y, Gardner TW, Padovani-Claudio DA. Bioelectric impact of pathological angiogenesis on vascular function. Proc Natl Acad Sci U S A. 2016 Aug;113(35):9934-9.

Newman-Casey PA, Shtein RM, Coleman AL, Herndon L, Lee PP. Why patients with glaucoma lose vision: the patient perspective.

J Glaucoma. 2016 Jul;25(7):e668-75.

Paulus YM, Johnson MW. Further evidence that cataract surgery is not associated with macular degeneration progression. JAMA Ophthalmol. 2016 Jun;134(6):627.

Rajala RV, Gardner TW. Burning fat fuels photoreceptors. Nat Med. 2016 Apr;22(4):342-3.

Nika M, Kalyani PS, Jayasundera KT, Comer GM. Pathogenesis of persistent placoid maculopathy: a multimodal imaging analysis. Retina. 2015 Aug;35(8):1531-9.

Paulus YM, Wenick AS. Development of chronic subretinal fluid in Kearns-Sayre syndrome. Retin Cases Brief Rep. 2016 Summer;10(3):236-8.

Novack GD, Robin AL. Ocular pharmacology. J Clin Pharmacol. 2016 May;56(5): 517-27.

Peeler CE, De Lott LB, Nagia L, Lemos J, Eggenberger ER, Cornblath WT. Clinical utility of acetylcholine receptor antibody testing in ocular myasthenia gravis. JAMA Neurol.

2015 Oct;72(10):1170-4.

Nudleman E, Wolfe JD, Woodward MA, Yonekawa Y, Williams GA, Hassan TS. Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab. Clin Ophthal. 2016 Jun;10:1053-7.

Oliver V, Jaffe AE, Song J, Wang G, Zhang P, Branham KE, Swaroop A, Eberhart CG, Zack DJ, Qian J, Merbs SL. Differential DNA methylation identified in the blood and retina of AMD patients. Epigenetics. 2015 Aug;10(8):698-707.

Pack W, Hill DD, Wong KY. Melatonin modulates M4-type ganglion-cell photoreceptors.

Neuroscience. 2015 Jul;303:178-88.

Parmar HA, Trobe JD. Hypoxic-ischemic encephalopathy with clinical and imaging abnormalities limited to occipital lobe.

J Neuroophthalmol. 2016 Sep;36(3):264-9.

Paulus YM, Butler NJ. Spectral-domain optical coherence tomography, wide-field photography, and fundus autofluorescence correlation of posterior ophthalmomyiasis interna.

Ophthalmic Surg Lasers Imaging Retina.

2016 Jul;47(7):682-5.

Paulus YM, Campbell JP. Neuroprotection and retinal diseases. Dev Ophthalmol.

2016;55:322-9.

Petty HR. Could nanoparticles that mimic the NADPH oxidase be used to kill tumor cells? Nanomedicine (Lond). 2016 Jul;11(13):1631-4.

Pham TD, Trobe JD. Selective unidirectional horizontal saccadic paralysis from acute ipsilateral pontine stroke. J Neuroophthalmol.

2016 Aug 10 [Epub ahead of print].

Prabhu SS, Shtein RM, Michelotti MM, Cooney TM. Topical cyclosporine A 0.05% for recurrent anterior uveitis. 2016 Mar;100(3):345-7.

Prum BE, Jr., Herndon LW, Jr., Moroi SE, Mansberger SL, Stein JD, Lim MC, Rosenberg LF, Gedde SJ, Williams RD. Primary angle closure preferred practice pattern guidelines.

Ophthalmology. 2016 Jan;123(1):P1-40.

Prum BE, Jr., Lim MC, Mansberger SL, Stein JD, Moroi SE, Gedde SJ, Herndon LW, Jr., Rosenberg LF, Williams RD. Primary openangle glaucoma suspect preferred practice pattern guidelines. Ophthalmology. 2016 Jan;123(1):P112-51.

Prum BE, Jr., Rosenberg LF, Gedde SJ, Mansberger SL, Stein JD, Moroi SE, Herndon LW, Jr., Lim MC, Williams RD. Primary open-angle glaucoma preferred practice pattern guidelines. Ophthalmology.

2016 Jan:P41-111.

Rao RC, Chan MP, Andrews CA, Kahana A. EZH2, proliferation rate, and aggressive tumor subtypes in cutaneous basal cell carcinoma.

JAMA Oncol. 2016 Jul;2(7):962-3.

Rao RC, Choudhry N. Cystoid macular edema associated with chemotherapy. CMAJ. 2016 Feb;188(3):216.

Rao RC, Cohen SR, Mian SI. Silicone oil retention sutures for retinal detachment repair following traumatic aniridia, aphakia, and ruptured globe. JAMA Ophthalmol. 2015 Sep;133(9):e151433.

Rao RC, Elner VM, Demirci H. A red and swollen eyelid. JAMA Oncol. 2015 Jul;1(4):537-8.

Rao RC, Gragoudas ES. Choroidal metastases from EML4-ALK-positive non-small-cell lung adenocarcinoma. J Clin Oncol. 2015 Oct;33(30):e112-e4.

Rao RC, Harbour JW. An iris tumor. JAMA Ophthalmol. 2016 Sep;134(9):1063-4.

Reifler AN, Chervenak AP, Dolikian ME, Benenati BA, Li BY, Wachter RD, Lynch AM, Demertzis ZD, Meyers BS, Abufarha FS, Jaeckel ER, Flannery MP, Wong KY. All spiking, sustained on displaced amacrine cells receive gap-junction input from melanopsin ganglion cells. Curr Biol. 2015 Nov;25(21):2763-73.

Ross EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial. JAMA Ophthalmol. 2016 Aug;134(8):888-96.

39

FACULTY PUBLICATIONS JULY 1, 2015 — SEPTEMBER 30, 2016

Ross EL, Stein JD. Enhancing the value of preschool vision screenings. JAMA Ophthalmol. 2016 Jun;134(6):664-5.

Saera-Vila A, Kasprick DS, Junttila TL, Grzegorski SJ, Louie KW, Chiari EF, Kish PE, Kahana A. Myocyte dedifferentiation drives extraocular muscle regeneration in adult zebrafish. Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4977-93.

Saera-Vila A, Kish PE, Kahana A. Automated scalable heat shock modification for standard aquatic housing systems. Zebrafish. 2015 Aug;12(4):312-4.

Saera-Vila A, Kish PE, Kahana A. FGF regulates dedifferentiation during skeletal muscle regeneration in adult zebrafish. Cell Signal.

2016 Sep;28(9):1196-204.

Sas KM‌ Abcouwer SF, Gardner TW, et al. Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications.

JCI Insight. 2016 Sep;1(15):e86976.

Scherer LD, Finan C, Simancek D, Finkelstein JI, Tarini BA. Effect of "pink eye" label on parents' intent to use antibiotics and perceived contagiousness. Clin Pediatr (Phila). 2016 Jun;55(6):543-8.

Sealy-Jefferson S, Vickers J, Elam A, Wilson MR. Racial and ethnic health disparities and the Affordable Care Act: a status update.

J Racial Ethn Health Disparities. 2015 Dec;2(4):583-8.

Sen D, SoRelle ED, Liba O, Dalal R, Paulus YM, Kim TW, Moshfeghi DM, de la Zerda A. High-resolution contrast-enhanced optical coherence tomography in mice retinae. J Biomed Opt. 2016 Jun;21(6):66002.

Sen HN, Abreu FM, Louis TA, Sugar EA, Altaweel MM, Elner SG, Holbrook JT, Jabs DA, Kim RY, Kempen JH. Cataract surgery outcomes in uveitis: the Multicenter Uveitis Steroid Treatment Trial. Ophthalmology. 2016 Jan;123(1):183-90.

40

Sengupta S, Venkatesh R, Krishnamurthy P, Nath M, Mashruwala A, Ramulu PY, Robin AL, Lee P. Intraocular pressure reduction after phacoemulsification versus manual small-incision cataract surgery: a randomized controlled trial. Ophthalmology. 2016 Aug;123(8): 1695-703.

Shah AR, Williams S, Baumal CR, Rosner B, Duker JS, Seddon JM. Predictors of response to intravitreal anti-vascular endothelial growth factor treatment of age-related macular degeneration. Am J Ophthalmol. 2016 Mar;163: 154-66.

Shah M, Law G, Ahmed II. Glaucoma and cataract surgery: two roads merging into one.

Curr Opin Ophthalmol. 2016 Jan;27(1):51-7.

Shelby SJ, Feathers KL, Ganios AM, Jia L, Miller JM, Thompson DA. MERTK signaling in the retinal pigment epithelium regulates the tyrosine phosphorylation of GDP dissociation inhibitor alpha from the GDI/CHM family of RAB GTPase effectors. Exp Eye Res. 2015 Nov;140:28-40.

Shtein RM, Newman-Casey PA, Herndon L, Coleman AL, Lee PP. Assessing the role of the family/support system perspective in patients with glaucoma. J Glaucoma. 2016 Jul;25(7):e676-80.

Singh RK, Mallela RK, Cornuet PK, Reifler AN, Chervenak AP, West MD, Wong KY, Nasonkin I. Characterization of three-dimensional retinal tissue derived from human embryonic stem cells in adherent monolayer cultures.

Stem Cells Dev. 2015 Dec;24(23):2778-95.

Skuta GL, Mattox CG, Stein JD. Effect of Medicare part D on the availability of medical treatment for patients with glaucoma. JAMA Ophthalmol. 2016 Feb;134(2):220-1.

Sleath B, Carpenter DM, Blalock SJ, Sayner R, Muir KW, Slota C, Giangiacomo AL, Hartnett ME, Tudor G, Robin AL. Applying the resources and supports in self-management framework to examine ophthalmologist-patient communication and glaucoma medication adherence.

Health Educ Res. 2015 Oct;30(5):693-705.

Smith TJ. Rational for therapeutic targeting insulin-like growth factor-1 receptor and bone marrow-derived fibrocytes in thyroid-associated ophthalmopathy. Exp Rev Ophthalmol. 2016 Apr;11(2):77-9.

Soelberg K, Larsen SR, Moerch MT, Thomassen M, Brusgaard K, Paul F, Smith TJ, Godballe C, Grauslund J, Lillevang ST, Asgari N. Aquaporin-4 IgG autoimmune syndrome and immunoreactivity associated with thyroid cancer. Neurol Neuroimmunol Neuroinflamm.

2016 Jun;3(4):e252.

Stacey AW, Demirci H. Serial intravitreal bevacizumab injections slow the progression of radiation maculopathy following iodine-125 plaque radiotherapy. Open Ophthalmol J. 2016 Mar;10:103-10.

Stacey AW, Gemmete JJ, Kahana A. Management of orbital and periocular vascular anomalies. Ophthal Plast Reconstr Surg. 2015 Nov-Dec;31(6):427-36.

Stein JD. Uncovering some of the hidden costs and burdens of glaucoma. JAMA Ophthalmol.

2016 Apr;134(4):365-6.

Stein JD, Andrews C, Musch DC, Green C, Lee PP. Sight-threatening ocular diseases remain underdiagnosed among children of less affluent families. Health Aff (Millwood). 2016 Aug;35(8):1359-66.

Steinman L, Bar-Or A, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Yeaman MR, Smith TJ. Restoring immune tolerance in neuromyelitis optica: Part I. Neurol Neuroimmunol Neuroinflamm. 2016 Sep;3(5):e276.

Stem MS, Blachley TS, Shtein RM, Herman WH, Gardner TW, Stein JD. Impact of diagnosing diabetic complications on future hemoglobin A levels. J Diabetes Complications.

2016 Mar;30(2):323-8.

Stem MS, Dunbar GE, Jackson GR, Farsiu S, Pop-Busui R, Gardner TW. Glucose variability and inner retinal sensory neuropathy in persons with type 1 diabetes mellitus. Eye (Lond).

2016 Jul;30(6):825-32.

FACULTY PUBLICATIONS JULY 1, 2015 — SEPTEMBER 30, 2016

Sugar A. The importance of corneal endothelial cell survival after endothelial keratoplasty.

JAMA Ophthalmol. 2015 Nov;133(11): 1285-6.

Tanaka TS, Demirci H. Cryopreserved ultra-thick human amniotic membrane for conjunctival surface reconstruction after excision of conjunctival tumors. Cornea.

2016 Apr;35(4):445-50.

Taylor SM, Alvarez-Delfin K, Saade CJ, Thomas JL, Thummel R, Fadool JM, Hitchcock PF. The bHLH transcription factor neuroD governs photoreceptor genesis and regeneration through delta-notch signaling. Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7496-515.

Thomas AS, Branham K, Van Gelder RN, Daiger SP, Sullivan LS, Bowne SJ, Heckenlively JR, Pennesi ME. Multimodal imaging in Wagner syndrome. Ophthalmic Surg Lasers Imaging Retina. 2016 Jun;47(6):574-9.

Thomas BJ, Mehta N, Yonekawa Y, Sridhar J, Kuriyan AE, Rehlan N, Liang MC, Woodward MA, Witkin AJ, Shah C, Flynn HW, Jr., Garg SJ, Wolfe JD. Pars plana vitrectomy for late vitreoretinal sequelae of infectious endophthalmitis: surgical management and outcomes. Retina. 2016 Jul 26 [Epub ahead of print].

Thomas M, Lim JI. Painful red eye in a woman in her 70s. JAMA Ophthalmol.

2016;134(2):233-4.

Thomas M, Shorter E, Joslin CE, McMahon TJ, Cortina MS. Contact lens use in patients with Boston keratoprosthesis type 1: fitting, management, and complications. Eye Contact Lens. 2015;41(6):334-40.

Thomas M, Vajaranant TS, Aref AA. Hypotony maculopathy: clinical presentation and therapeutic methods. Ophthalmol Ther.

2015;4(2):79-88.

Thomas M, Wolfson Y, Zayit-Soudry S, Bressler SB, Bressler NM. Qualifying to use a home monitoring device for detection of neovascular age-related macular degeneration.

JAMA Ophthalmol. 2015;133(12):1425-30.

Todorich B, Thanos A, Woodward MA, Wolfe JD. Sutureless intrascleral fixation of secondary intraocular lens using 27-gauge vitrectomy system. Ophthalmic Surg Lasers Imaging Retina. 2016 Apr;47(4):376-9.

Vartanian GV, Li BY, Chervenak AP, Walch OJ, Pack W, Ala-Laurila P, Wong KY. Melatonin suppression by light in humans is more sensitive than previously reported. J Biol Rhythms.

2015 Aug;30(4):351-4.

Tomkins-Netzer O, Lightman S, Drye L, Kempen J, Holland GN, Rao NA, Stawell RJ, Vitale A, Jabs DA, Elner SG. Outcome of treatment of uveitic macular edema: the Multicenter Uveitis Steroid Treatment Trial 2-Year results. Ophthalmology. 2015 Nov;122(11):2351-9.

Vartanian GV, Zhao X, Wong KY. Using flickering light to enhance nonimage-forming visual stimulation in humans. Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4680-8.

Tozer K, Woodward MA, Newman-Casey PA. Telemedicine and diabetic retinopathy: review of published screening programs. J Endo Diab. 2015 Oct;2(4):1-10.

Trese MG, Khan NW, Branham K, Conroy EB, Moroi SE. Expansion of severely constricted visual field using Google glass.

Ophthalmic Surg Lasers Imaging Retina. 2016 May;47(5):486-9.

Trese MG, Nudleman ED, Besirli CG. Peripheral retinal vasculopathy in cockayne syndrome. Retin Cases Brief Rep. 2016 Apr 27 [Epub ahead of print].

Undavia S, Briceno CA, Massry GG. Quantified incision placement for postseptal approach transconjunctival blepharoplasty. Ophthal Plast Reconstr Surg. 2016 May-Jun;32(3):191-4.

Vadlamudi V, Gemmete JJ, Chaudhary N, Pandey AS, Kahana A. Transvenous sclerotherapy of a large symptomatic orbital venous varix using a microcatheter balloon and bleomycin. J Neurointerv Surg. 2016 Aug;8(8):e30.

Vora GK, Demirci H, Marr B, Mruthyunjaya P. Advances in the management of conjunctival melanoma. Surv Ophthalmol. 2016 Jun 16 [Epub ahead of print].

Walch OJ, Zhang LS, Reifler AN, Dolikian ME, Forger DB, Wong KY. Characterizing and modeling the intrinsic light response of rat ganglion-cell photoreceptors. J Neurophysiol.

2015 Nov;114(5):4336-44.

Wang H, Atkins SJ, Fernando R, Wei RL, Smith TJ. Pentraxin-3 is a TSH-inducible protein in human fibrocytes and orbital fibroblasts.

Endocrinology. 2015 Nov;156(11):4336-44.

Wang JC, Campos-Moller X, Shah M, Sheybani A, Ahmed II. Effect of endocyclophotocoagulation on refractive outcomes in angle-closure eyes after phacoemulsification and posterior chamber intraocular lens implantation. J Cataract Refract Surg. 2016 Jan;42(1):132-7.

Wang SY, Blachley TS, Andrews CA, Ayanian JZ, Lee PP, Stein JD. Hospitalization after cataract surgery in a nationwide managed-care population. PLoS One. 2016 Feb;11(2):e0149819.

Valikodath NG, Leveque TK, Wang SY, Lee PP, Newman-Casey PA, Hansen SO, Woodward MA. Patient attitudes toward telemedicine for diabetic retinopathy. Telemed J E Health. 2016 Jun 23 [Epub ahead of print].

Wang SY, Ghodasra DH, Amin SR, Mian SI, Jayasundera KT. Fungal endophthalmitis associated with DSAEK and thermal sclerostomy. Ophthalmic Surg Lasers Imaging Retina.

2016 Jul;47(7):691-3.

Vartanian GV, Li BY, Chervenak AP, Walch OJ, Pack W, Ala-Laurila P, Wong KY. Melatonin suppression by light in humans is more sensitive than previously reported. J Biol Rhythms.

2015 Aug;30(4):351-4.

Wassmer S, Leonard BC, Coupland SG, Baker A, Hamilton J, Torlone R, Zacks DN, Tsilfidis C. The development of a cat model of retinal detachment and re-attachment. Adv Exp Med Biol. 2016;854:315-21.

41

FACULTY PUBLICATIONS JULY 1, 2015 — SEPTEMBER 30, 2016

Wei Y, Kang XL, Del Monte MA. Enlargement of the superior rectus and superior oblique muscles causes intorsion in Graves' eye disease.

Br J Ophthalmol. 2016 Sep;100(9):1280-4.

Weidmayer SL. Recognize the signs of ocular melanoma. Rev Optom. 2015 Nov;152(11):65-73.

Weisschuh N‌ Heckenlively JR, et al.

Mutation detection in patients with retinal dystrophies using targeted next generation sequencing. PLoS One. 2016 Jan;11(1):e0145951.

Witkin AJ, Shah AR, Engstrom RE, Kron-Gray MM, Baumal CR, Johnson MW, Witkin DI, Leung J, Albini TA, Moshfeghi AA, Batlle IR, Sobrin L, Eliott D. Postoperative hemorrhagic occlusive retinal vasculitis: expanding the clinical spectrum and possible association with vancomycin. Ophthalmology. 2015 Jul;122(7):1438-51.

Wolle MA, Estopinal CB, Sugar A. April consultation #2. J Cataract Refract Surg. 2016 Apr;42(4):638.

Wolle MA, Randleman JB, Woodward MA. Complications of refractive surgery: ectasia after refractive surgery. Int Ophthalmol Clin.

2016 Spring;56(2):129-41.

Wong SH, Plant GT, Cornblath W. Does treatment of ocular myasthenia gravis with early immunosuppressive therapy prevent secondarily generalization and should it be offered to all such patients? J Neuroophthalmol. 2016 Mar;36(1):98-102.

Woodward MA, Bavinger JC, Amin S, Blachley TS, Musch DC, Lee PP, Newman-Casey PA. Telemedicine for ophthalmic consultation services: use of a portable device and layering information for graders. J Telemed Telecare. 2016 Mar 1 [Epub ahead of print].

42

Woodward MA, Blachley TS, Stein JD. The association between sociodemographic factors, common systemic diseases, and keratoconus: an analysis of a nationwide heath care claims database. Ophthalmology. 2016 Mar;123(3):457-65.

Wu CY, Archer SM, Kahana A. "Tag-team" orbital and strabismus surgeries with immediate reconstruction after tumor excision metastatic to the inferior rectus. Ophthal Plast Reconstr Surg.

2016 Jan-Feb;32(1):e7-8.

Wu CY, Elner VM, Kahana A. Severe pediatric thyroid eye disease: surgical case series. Ophthal Plast Reconstr Surg. 2015 Oct 30 [Epub ahead of print].

Wu CY, Kahana A. Stereotactic navigation with a registration mask in orbital decompression surgery: preliminary results. Ophthal Plast Reconstr Surg. 2015 Nov-Dec;31(6):440-4.

Wu CY, Niziol LM, Musch DC, Kahana A. Thyroid-related orbital decompression surgery: a multivariate analysis of risk factors and outcomes. Ophthal Plast Reconstr Surg. 2016 Apr 19 [Epub ahead of print].

Wu T, Mester T, Gupta S, Sun F, Smith TJ, Douglas RS. TSH and CD40L stimulate interleukin-12 expression in fibrocytes: implications for pathogenesis of thyroid associated ophthalmopathy. Thyroid. 2016 Sep 9 [Epub ahead of print].

Wubben TJ, Besirli CG, Zacks DN. Pharmacotherapies for retinal detachment. Ophthalmology. 2016 Jul;123(7):1553-62.

Wubben TJ, Talwar N, Blachley TS, Gardner TW, Johnson MW, Lee PP, Stein JD. Rates of vitrectomy among enrollees in a United States managed care network, 2001-2012.

Ophthalmology. 2016 Mar;123(3):590-8.

Yan N, Cheng L, Cho K, Malik MT, Xiao L, Guo C, Yu H, Zhu R, Rao RC, Chen DF. Postnatal onset of retinal degeneration by loss of embryonic Ezh2 repression of Six1. Sci Rep. 2016 Sep;6:33887.

Zhang F, Sugar A, Arbisser L, Jacobsen G, Artico J. Crossed versus conventional pseudophakic monovision: patient satisfaction, visual function, and spectacle independence. J Cataract Refract Surg. 2015 Sep;41(9):1845-54.

Zhang H, Gayen S, Xiong J, Zhou B, Shanmugam AK, Sun Y, Karatas H, Liu L, Rao RC, Wang S, Nesvizhskii AI, Kalantry S, Dou Y. MLL1 inhibition reprograms epiblast stem cells to naive pluripotency. Cell Stem Cell. 2016 Apr;18(4):481-94.

Zhang L, Blachley TS, Weizer JS. Baerveldt 250 mm2 glaucoma drainage devices in eyes with preexisting scleral buckles. J Glaucoma.

2016 Mar;25(3):285-90.

Zhang S, Liang Y, Chen Y, Musch DC, Zhang C, Wang N. Utility analysis of vision-related quality of life in patients with glaucoma and different perceptions from ophthalmologists.

J Glaucoma. 2015 Sep;24(7):508-14.

Zhao X, Pack W, Khan NW, Wong KY. Prolonged inner retinal photoreception depends on the visual retinoid cycle. J Neurosci. 2016 Apr;36(15):4209-17.

Zhou B, Wang J, Lee SY, Xiong J, Bhanu N, Guo Q, Ma P, Sun Y, Rao RC, Garcia BA, Hess JL, Dou Y. PRDM16 suppresses MLL1r leukemia via intrinsic histone methyltransferase activity. Mol Cell. 2016 April;62(2):222-36.

EXTERNAL GRANTS AND FUNDING FA CULTY N A M E

JULY 1, 2015 — SEPTEMBER 30, 2016

P ROJ EC T T IT L E

SO UR C E

S. Abcouwer, Ph.D. Bone Marrow Neuropathy Drives Diabetic Retinopathy; multi-PI Subcontract with Indiana University-Purdue University Indianapolis

Integrated Systems Biology Approach to Diabetic Microvascular Complications; multi-PI

Examine Effect Senolytic Drug Compound Retinal Ganglion Cell

NIH

D. Antonetti, Ph.D. Discovering Novel Atypical PKC Inhibitors as in vivo Chemical Probes

Mechanisms of Retinal Vascular Permeability in Diabetes

Novel Therapies to Inhibit Diabetic Retinopathy Subcontract with Case Western University

Structural Studies of Tight Junction Proteins Subcontract with Pennsylvania State University

The Retinal Microenvironment in Diabetic Retinopathy Subcontract with Northwestern University

Norrin as a Potential Therapy for Diabetic Retinopathy

Testing in mDia1 Knockout for Retinal Pathology in Diabetes and Ischemia Reperfusion

CCL2 Trap for Diabetic Retinopathy

Effects of Intravitreal mU1 on the Pathological Responses to Retinal Ischemia-Reperfusion Injury

Jules and Doris Stein RPB Professorship

NIH NIH NIH

S. Archer, M.D. Ocular Toxicity of Combined Carboplatin and Etoposide Phosphate Intravitreal Injection Therapy (IViT) for Retinoblastoma

The Knights Templar Foundation, Inc.

C. Besirli, M.D., Ph.D. Neuroprotection in Pediatric Retinal Detachment

Cryoanesthesia - Rapid Anesthesia for Intraocular Injections

A Randomized, Open-Label, Controlled, Multicenter Study to Compare the Efficacy and Safety of Intravitreal Ranibizumab with Laser Therapy in Patients with Retinopathy of Prematurity

Testing of ONL Compounds in Retinal Cell Apoptosis Models

Career Development Award: Stress-Induced Neuroprotection in the Retina

NIH State of Michigan Novartis

B. Bohnsack, M.D., Ph.D. Regulation of Ocular Neural Crest and Its Implications in Congenital Eye Diseases

Retinoic Acid Regulation of Anterior Segment Maintenance in a Zebrafish Model of Glaucoma

Zebrafish Model of Primary Congenital Glaucoma: Understanding CYP1B1 Regulation of Eye Development

Career Development Award: A Zebrafish Model for Congenital Eye Disease

NIH Alcon Laboratories, Inc.

G. Comer, M.D., M.S. Treatment for Central-Involved Diabetic Macular Edema in Eyes Coordinating Center: Jaeb Center for Health Research

Structural and Functional Relationships of the Retina in Diabetic Macular Edema

A Natural History Study of Macular Telangiectasia—The MacTel Study

A Phase 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel)

A Multi-Center, Two-Stage, Open-Label Phase I and Randomized, Active Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology Compared with Eylea for the Treatment of Recurrent Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

NIH

W. Cornblath, M.D.

Merck Research Labs

Educational Subsidy for Healthcare Professionals-in-Training

L. De Lott, M.D. A Phase 2/3, Randomized, Double-Masked, Sham Controlled Trial of QPI-1007 Delivered by Single or Multi-Dose Intravitreal Injection(s) to Subjects with Acute Nonarteritic Anterior Ischemic Optic Neuropathy

NIH Unity Biotechnology

NIH NIH American Diabetes Association, Inc. New York University Novo Nordisk Novo Nordisk RPB

ONL Therapeutics RPB

Edward Mallinckrodt Jr. Foundation RPB

JDRF LMRI LMRI Neurotech USA, Inc.

Quark Pharmaceuticals, Inc.

43

EXTERNAL GRANTS AND FUNDING FA CULTY N A M E

JULY 1, 2015 — SEPTEMBER 30, 2016

P ROJ EC T T IT L E

SO UR C E

M. Del Monte, M.D. A 3-month, Multi-Center, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patient

An Observational, Multicenter Study of the Prevalence of Cerebrotendinous Xanthomatosis in Patient Populations Diagnosed with Early-Onset Idiopathic Bilateral Cataracts

Alcon Laboratories, Inc.

R. Douglas, M.D., Ph.D. Role of CD40+ Fibrocytes in Thyroid-Associated Ophthalmopathy

A Multicenter, Double-Masked, Placebo-Controlled Efficacy and Safety Study of RV001, an Insulin-like Growth Factor-1Receptor (IGF-1R) Antagonist Antibody (fully human), Administered Every 3 Weeks (Q3W) by Intravenous (IV) Infusion in Patients Suffering from Active Thyroid Eye Disease (TED)

Lew R. Wasserman Merit Award: Role of Fibrocytes in Thyroid-Activated Ophthalmopathy

NIH River Vision LLC

J. Ehrlich, M.D.

MICHR

Optical Head-Mounted Display Technology for Low Vision Rehabilitation

S. Elner, M.D. Macular Edema Treatment Trials Associated with MUST (META-MUST) Coordinating Center: Johns Hopkins University

A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

Retrophin, LLC

RPB

NIH Santen Pharmaceutical

P. Fort, Ph.D., M.S. Progressive Impact of Diabetes on Retinal Neuroprotection by Îą-Crystallins NIH

Role of Crystallins in the Neurodegenerative and Neuroinflammatory Components NIH of Human Diabetic Retinopathy; Subcontract with University of Georgia

Regional Alterations of the Human Retinal Transcriptome During Diabetes Eversight

Regulation of Crystallin Neuroprotective Function in the Retina During International Retinal Research Diabetes: Impact on Retinal Ganglion Cell Death Foundation P. Gage, Ph.D.

44

Essential Functions of PITX2 in Cornea, Iris, and Iridocorneal Angle Development Analysis of Ocular Functions of CHD7 in Mouse Models of CHARGE Syndrome

NIH CHARGE Syndrome Foundation, Inc.

T. Gardner, M.D., M.S. Diabetic Retinopathy Clinical Research Network Coordinating Center: Jaeb Center for Health Research

Genes in Diabetic Retinopathy Coordinating Center: Jaeb Center for Health Research

Metabolic Reprogramming in Diabetic Complications; multi-PI

Michigan Vision Clinician-Scientist Development Program; multi-PI

Regulation of Retinal Cell Death in Diabetes; multi-PI

Clinical Research Training in Diabetic Macular Edema

Evaluation of Retinal Sensory Neuropathy

Physician-Scientist Award: Diabetic Retinal Sensory Neuropathy

Retina Research Foundation Award

NIH

J. Heckenlively, M.D. More Complete Assessment Of DNA Variation in Age-Related Macular Degeneration Subaccount with Goncalo Abecasis, D.Phil., School of Public Health, Univ. of Michigan

A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-Associated Virus Vector Expressing Retinoschisin in Patients with X-Linked Retinoschisis

Clinical Evaluation of Individuals with X-linked Retinoschisis

Research Center for the Study of Retinal Degenerative Diseases

Retinitis Pigmentosa Natural History Study of Patients with the P23H Mutation of the Rhodopsin Gene

A Phase II, Multiple-Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Retinitis Pigmentosa

NIH

NIH NIH NIH NIH Bayer HealthCare JDRF RPB Retina Research Foundation

Applied Genetic Technologies Corp.

FFB FFB Ionis Pharmaceuticals NNRI

EXTERNAL GRANTS AND FUNDING

JULY 1, 2015 — SEPTEMBER 30, 2016

FA CULTY N A M E

P ROJ EC T T IT L E

SO UR C E

P. Hitchcock, Ph.D.

Neuronal Development, Injury and Repair in Retina Vision Research Training Program

NIH NIH

B. Hughes, Ph.D.

Core Center for Vision Research (five core modules) Ion Conductances in the Retinal Pigment Epithelium

NIH NIH

K.T. Jayasundera, M.D.

Targeted Functional Testing for Retinal Diseases Based on Patient Reported Outcomes eSight Quality of Life and Efficacy Study (eQUEST) EDI-OCT Choroidal Evaluation in Patients with Choroideremia University Technology Acceleration and Commercialization (UTACP) Post-Approval Study of the Argus II Retinal Prosthesis System Fast Forward Medical Innovation

NIH eSight Corporation FFB State of Michigan Second Sight Medical Products, Inc William Davidson Foundation

M. Johnson, M.D. Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Genentech, Inc.

A. Kahana, M.D., Ph.D.

A Zebrafish Model of Extraocular Muscle Regeneration Genetic Regulation of Extraocular Muscle Repair and Regeneration The Role of Retinoic Acid in Regulating Thyroid Eye Disease VISmodegib as Neo-adjuvant for ORBital and Periocular Basal Cell Carcinoma (VISORB) Lacrimal Stent with Opening to Improve Draining Efficacy and Reduce Infection Fast Forward Medical Innovation

NIH Alliance for Vision Research Alliance for Vision Research Genentech, Inc. State of Michigan William Davidson Foundation

P. Lee, M.D., J.D.

Vision Health Initiative - IPA with CDC Unrestricted Grant Child Vision Care Fund

NIH RPB W.K. Kellogg Foundation

M. Lipson, O.D.

Overnight Corneal Reshaping - Quality of Life (OCRQL) Survey Instrument

Bausch & Lomb, Inc.

S. Mian, M.D. Lab Sample Collection Avellino Laboratory USA, Inc.

Cross Sectional Study of Prevalence of TGFBI Corneal Dystrophies Avellino Laboratory USA, Inc.

A Prospective, Multicenter, Post-Approval Study of Vision Care’s Implantable VisionCare Ophthalmic Miniature Telescope (by Dr. Isaac Lipshitz) in Patients with Bilateral Severe to Technologies, Ltd. Profound Central Vision Impairment Associated with End-Stage Age-Related Macular Degeneration S. Moroi, M.D., Ph.D. Aqueous Humor Dynamic Components that Determine Intraocular Pressure Variance

Ocular Hypertension Treatment Study 20-Year Follow-Up Subcontract with Washington University

A Prospective, Double-Masked, Randomized, Multi-Center, Active-Controlled, Parallel-Group 12-Month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to AR-13324 Ophthalmic Solution and Latanorprost Ophthalmic Solution in Subjects with Elevated Intraocular Pressure

The Efficacy and Safety of Bimatoprost SR in Patients with Open-Angle Glaucoma or Ocular Hypertension

NIH

D. Musch, Ph.D., M.P.H.

NIH

Assessing the Impact of Glaucoma and Its Treatment on the Person

P. Newman-Casey, M.D., M.S. Improving Glaucoma Self-Management with Technology-Supported Counselors

Adherence to Glaucoma Medications

A Counseling Training Program for Glaucoma Staff: Development and Preliminary Assessment

Creating and Evaluating a Counseling Training Program for Glaucoma Staff

David L. Epstein, MD Clinician Scientist Research Award

The eyeGuide: Evaluating the Impact of a Personally Tailored Behavior Change Program for Glaucoma Patients

NIH Aerie Pharmaceuticals, Inc.

Allergan Pharmaceuticals, Inc.

NIH Allergan Pharmaceuticals, Inc. American Glaucoma Society Blue Cross Blue Shield of Michigan Chandler-Grant Glaucoma Society RPB

45

EXTERNAL GRANTS AND FUNDING FA CULTY N A M E

JULY 1, 2015 — SEPTEMBER 30, 2016

P ROJ EC T T IT L E

SO UR C E

Y. Paulus, M.D. Real-time in vivo Visualization of Molecular Processes in Rentinal and Choroidal Neovascularization

Fight for Sight, Inc.

D. Puro, M.D., Ph.D. Retinovascular Pathophysiology: Focus on Proliferative Retinopathy

Stein Innovation Award: A Novel Experimental Approach to Dry Eye: Role of Ion Channels in the Physiology and Pathobiology of Conjunctival Goblet Cells

NIH RPB

R. Rao, M.D. Targeting EZH2-TET3 Epigenetic Axis in Human Retinoblastoma

Sustaining Early-Born Retinal Neuron Potency from Stem Cells: An Epigenetic Approach

Targeting EZH2, a Histone Methyltransferase, as a Novel Therapy for Human Retinoblastoma

Alcon Laboratories, Inc. RPB

J. Richards, Ph.D. NEIGHBORHOOD Consortium for POAG Genomics; Subcontract with MEEI

Genetics of Homocycteine Metabolism in Glaucoma

Mechanics of Intraocular Pressure Increase Associated with Genetic Factors; multi-PI Subaccount with Alan Argento, Ph.D., Mechanical Engineering, Univ. of Michigan Dearborn

REU Supplement: Mechanics of Intraocular Pressure

NIH BrightFocus Foundation NSF

A. Shah, M.D. Peripheral Diabetic Retinopathy (DR) Lesions on Ultrawide-Field Fundus Images and Risk of Diabetic Retinopathy Worsening Over Time Coordinating Center: Jaeb Center for Health Research

NIH

R. Shtein, M.D., M.S. Assessment of Dry Eye Symptom Severity (DREAM study) Subcontract with University of Pennsylvania

Multinational, Collaborative Evaluation of Corneal Confocal Microscopy as a Surrogate Endpoint for the Identification and Prediction of Diabetic Neuropathy in Type 1 Diabetes; Subcontract with Mount Sinai Hospital

T. Smith, M.D. Autoimmunity Center of Excellence Clinical Research Subaccount with David A. Fox, M.D., Internal Medicine, Univ. of Michigan Subcontract with University of California San Francisco

Regulation of Retroocular Connective Tissue

UM-ACE: ACE Collaborative Project Subaccount with David A. Fox, M.D., Internal Medicine, Univ. of Michigan

Physician-Scientist Award

NIH

J. Stein, M.D., M.S. Collaboration on Cost-Effectiveness Analyses--DRCR Network, Subcontract with JAEB Center for Health Research

Oral Microbiome and Periodontitis: A Prospective Study in Postmenopausal Women Subcontract with the Research Foundation of the City University of New York

Personalized Forecasting of Disease Trajectory for Patients with Open-Angle Glaucoma; multi-PI

Women's Health Initiative Subcontract with the State University of New York

Relationship Between Components of Metabolic Syndrome and Open-Angle Glaucoma

Relative Workforce Data of Eye Care Providers

Impact of Losartan Use on the Risk of Developing Open-Angle Glaucoma

Using Claims Data to Compare the Safety of Glaucoma Drainage Device vs.

Trabeculectomy With and Without Shunt

Assessment of the Relation between Medications for Epilepsy and Risk of Developing Open-Angle Glaucoma

NIH

46

The Knights Templar Foundation, Inc.

NSF

NIH

NIH

NIH NIH RPB

NIH NIH NIH Blue Cross Blue Shield of Michigan American Academy of Ophthalmology American Glaucoma Society American Glaucoma Society Harvard University

EXTERNAL GRANTS AND FUNDING FA CULTY N A M E

JULY 1, 2015 — SEPTEMBER 30, 2016

P ROJ EC T T IT L E

SO UR C E

J. Stein, M.D., M.S. (cont.) Do Patients with Vision Loss Use More Healthcare Services and Incur Higher Overall Lighthouse Guild Healthcare Costs? The Role of Vision Diagnosis and Visual Function

Risk of Malignancy in Ocular Inflammation Patients Treated With Anti-TNF-Alpha Therapies MEEI

Physician-Scientist Award: Understanding the Relationship between Components of RPB Metabolic Syndromes and Open-Angle Glaucoma

Monitoring Patients with Glaucoma Using a Novel Personalized Forecasting Tool State of Michigan

The Epidemiology of Macular Holes and Whether Use of Medication University of California Containing Estrogen Affect Development of Macular Holes San Francisco

Are Medications Used to Treat HIV and Hepatitis Beneficial in Preventing University of Kentucky Macular Degeneration

Assessment of the Relation Between Use of Medications to Treat HIV and Risk of University of Kentucky Developing Macular Degeneration A. Sugar, M.D. Central IRB Review of Local Context in Emergency Research: Empirical Ethics Study Subaccount with Robert Silibergleit, M.D., Emergency Medicine, Univ. of Michigan

Corneal Preservation Time Study, Coordinating Center: Jaeb

NIH

D. Thompson, Ph.D.

Control of Innate Inflammatory Responses in the Retina Gene-Replacement Therapy for RDH12 Mutations

BrightFocus Foundation RDH12 Fund for Sight

J. Trobe, M.D.

Automated Diplopia Assessment System (ADAS) MCRN Match

Medar Corporation

NIH

K. Wong, Ph.D. Physiology of Intrinsically Photosensitive Rentinal Ganglion Cells

Diversity Supplement: Physiology of Intrinsically Photosensitive Retinal Ganglion Cells

William & Mary Greve Special Scholar Award: Intraretinal Signaling by Intrinsically Photosensitive Retinal Ganglion Cells

Aro 3.3 Biomathematics Program: Modeling Subconscious Vision

Subcontract with Daniel Forger, Ph.D., Computational Medicine & Bioinformatics, Univ. of Michigan

Identification of Novel Drug Target for Retinal Disorders; multi-PI

NIH NIH RPB

M. Woodward, M.D., M.S. Telemedicine For Anterior Eye Diseases

Development of Clinical Tools for Telemedicine in Ophthalmology

Re-Design of Diabetic Retinopathy Patients Materials

NIH Alliance for Vision Research Intelligent Retinal Imaging Systems

D. Zacks, M.D., Ph.D. Autophagy and Control of Photoreceptor Apoptosis

Autophagy and Control of Photoreceptor Cell Death in Autosomal Dominant Retinitis Pigmentosa

Physician – Scientist Award: Dysregulation of RPE Autophagy and Age-related

Macular Degeneration

NIH Bayer HealthCare

US Department of Defense

Zietchick Research Institute LLC

RPB

SOURCE ABBREVIATIONS

MICHR ... University of Michigan Institute for Clinical & Health Research

FFB ....... Foundation Fighting Blindness

NIH ....... National Institutes of Health

JDRF ..... Juvenile Diabetes Research Foundation International

NNRI ..... National Neurovision Research Institute

LMRI ...... Lowy Medical Research Institute

NSF ....... National Science Foundation

MEEI ..... Massachusetts Eye and Ear Infirmary

RPB ....... Research to Prevent Blindness

47

2016 KELLOGG EYE CENTER FACULTY, RESIDENTS, AND FELLOWS

Faculty of the Department of Ophthalmology and Visual Sciences Steven Abcouwer, Ph.D. Robin Ali, BSc, Ph.D. Rami Al-Omari, M.D. David Antonetti, Ph.D. Erica Archer, M.D. Steven Archer, M.D. Bernadette Ayres, M.D. Terry Bergstrom, M.D. Cagri Besirli, M.D., Ph.D. Jill Bixler, M.D. Brenda Bohnsack, M.D., Ph.D. Kari Branham, MS, CGC Grant Comer, M.D. M.S. Theresa Cooney, M.D. Wayne Cornblath, M.D. Sherry Day, O.D. Lindsey De Lott, M.D. Vaidehi Dedania, M.D. Monte Del Monte, M.D. Karen DeLoss, O.D. Hakan Demirci, M.D. Laxmi Devisetty, M.D. Courtney Dewey, O.D. Raymond Douglas, M.D., Ph.D. Joshua Ehrlich, M.D., MPH Angela Elam, M.D. Susan Elner, M.D. Victor Elner, M.D., Ph.D. Abigail Fahim, M.D., Ph.D. Cherie Farkash, O.D. Jerome Finkelstein, M.D. Patrice Fort, Ph.D. Carlton Foster, O.D. Bruce Furr, C.O., Ph.D. Philip Gage, Ph.D. Christopher Gappy, M.D. Thomas Gardner, M.D., M.S. Daniel Green, Ph.D. Paul Grenier, O.D. John Heckenlively, M.D. Peter Hitchcock, Ph.D. Christopher Hood, M.D. Bret Hughes, Ph.D. Ida Iacobucci, C.O. Diane Jacobi, O.D. Pimkwan Jaru-Ampornpan, M.D. K. Thiran Jayasundera, M.D. Vanitha Jeyaraj, M.D. Denise John, M.D. Mark Johnson, M.D. Alon Kahana, M.D., Ph.D. Shivani Kamat, M.D. Ariane Kaplan, MD Harjeet Kaur, M.D. Naheed Khan, Ph.D. Denise Kim, M.D. Zvi Kresch, M.D. Michelle Kron-Gray, M.D., Ph.D.

Amy Lagina, O.D. Paul Lee, M.D., J.D. Helios Leung, O.D., Ph.D. Paul Lichter, M.D., M.S. Philip Lieu, M.D. Cheng-mao Lin, Ph.D. Michael Lipson, O.D. Xuwen Liu, M.D., Ph.D. Jordan Masters, M.D. Shahzad Mian, M.D. Sayoko Moroi, M.D., Ph.D. David Musch, Ph.D. M.P.H. Christine Nelson, M.D. Paula Anne Newman-Casey, M.D., M.S. Gale Oren, MILS Purak Parikh, M.D. Yannis Paulus, M.D. Howard Petty, Ph.D. Shreya Prabhu, M.D. Donald Puro, M.D., Ph.D. Joanna Queen, M.D. Rajesh Rao, M.D. Julia Richards, Ph.D. Alan Robin, M.D. Julie Rosenthal, M.D. Frank Rozsa, Ph.D. Gary Sandall, M.D. Jill Schafer, O.D. Kira Segal, M.D. Anjali Shah, M.D. Manjool Shah, M.D. Roni Shtein, M.D. Sujata Singh, M.D. Terry Smith, M.D. Michael Smith-Wheelock, M.D. H. Kaz Soong, M.D. William Sray, M.D. Brian Stagg, M.D. Joshua Stein, M.D., M.S. Jeffrey Stern, M.D., Ph.D. Alan Sugar, M.D. Jeffrey Sundstrom, M.D., Ph.D. Bradley Taylor, O.D., M.P.H. Sally Temple, M.D. Merina Thomas, M.D. Debra Thompson, Ph.D. Jonathan Trobe, M.D. Joshua Vrabec, M.D. Sara Weidmayer, O.D. Jennifer Weizer, M.D. Adrienne West, M.D. Donna Wicker, O.D. Kwoon Wong, Ph.D. Sarah Wood, O.D., M.S. Maria Woodward, M.D., M.S. Rebecca Wu, M.D. David Zacks, M.D., Ph.D.

All of us at the Kellogg Eye Center are committed to improving lives through curing, preventing, and treating eye disease.

Our guiding principles are teamwork, caring, innovation, and integrity.

Executive Officers of Michigan Medicine Marschall S. Runge, M.D., Ph.D. Executive Vice President for Medical Affairs, Dean of the Medical School, and CEO, Michigan Medicine David A. Spahlinger, M.D. Executive Vice Dean for Clinical Affairs and President of the Hospitals, Health Centers, and U-M Medical Group T. Anthony Denton, J.D., M.H.A. Senior Vice President and Chief Operating Officer for the Hospitals, Health Centers, and U-M Medical Group The Regents of the University of Michigan Michael J. Behm, Mark J. Bernstein, Shauna Ryder Diggs, Denise Ilitch, Andrea Fischer Newman, Andrew C. Richner, Ron Weiser, Katherine E. White, Mark S. Schlissel (ex officio) Editors: Jonathan Trobe, M.D., Julie Rosenthal, M.D. Writers: Shelley Zalewski, MargaretAnn Cross Editorial Assistant: Lisa Burkhart Design and Art Direction: David Murrel Photographers: Scott Soderberg, Austin Thomason, Michigan Photography; Lin Goings, U-M Department of Ophthalmology and Visual Sciences; Leisa Thompson Photography

FOR PATIENT APPOINTMENTS, PLEASE CALL 734.763.8122 For additional copies, please contact us: University of Michigan Department of Ophthalmology and Visual Sciences W.K. Kellogg Eye Center 1000 Wall Street Ann Arbor, Michigan 48105 www.kellogg.umich.edu

University of Michigan W.K. Kellogg Eye Center Department of Ophthalmology and Visual Sciences 1000 Wall Street Ann Arbor, MI 48105

Kellogg Among Nation’s Best in Eye Care #

9

OPHTHALMOLOGY IN THE NATION

The University of Michigan Kellogg Eye Center is proud to be ranked #9 in the country by U.S. News & World Report for being among the nation’s best in providing outstanding care for the most complex eye conditions.

Kellogg has seen extraordinary growth in all aspects of patient care, research, and education since the department was established in 1872. Every day, our clinicians, scientists, trainees, and staff work together to shape the future of eye care and vision science. The Kellogg team is especially proud of these recent accomplishments: • Kellogg is one of the top eye centers in the world for training the next generation of physician-scientists. In 2016, Doximity ranked us in the top 10 resident education programs. We are ranked #7 nationwide in research.

• Kellogg has the most faculty K training grants of any ophthalmology department in the country.

• Kellogg physicians are leaders in international ophthalmology, with more than ten platforms around the world.

2016 U.S. NEWS & WORLD REPORT’S “BEST HOSPITALS”